Examining the Regulation of Kv7 K+ Channels in Airway Smooth Muscle Cells and Their Potential as Novel Therapeutic Targets for the Treatment of Asthma by Haick, Jennifer
Loyola University Chicago 
Loyola eCommons 
Dissertations Theses and Dissertations 
2017 
Examining the Regulation of Kv7 K+ Channels in Airway Smooth 
Muscle Cells and Their Potential as Novel Therapeutic Targets for 
the Treatment of Asthma 
Jennifer Haick 
Loyola University Chicago 
Follow this and additional works at: https://ecommons.luc.edu/luc_diss 
 Part of the Pharmacology Commons 
Recommended Citation 
Haick, Jennifer, "Examining the Regulation of Kv7 K+ Channels in Airway Smooth Muscle Cells and Their 
Potential as Novel Therapeutic Targets for the Treatment of Asthma" (2017). Dissertations. 2588. 
https://ecommons.luc.edu/luc_diss/2588 
This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. 
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more 
information, please contact ecommons@luc.edu. 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. 






LOYOLA UNIVERSITY CHICAGO 
 
EXAMINING THE REGULATION OF Kv7 K+ CHANNELS IN AIRWAY SMOOTH 
 MUSCLE CELLS AND THEIR POTENTIAL AS NOVEL THERAPEUTIC  
TARGETS FOR THE TREATMENT OF ASTHMA 
 
A DISSERTATION SUBMITTED TO 
THE FACULTY OF THE GRADUATE SCHOOL 
IN CANDIDACY FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 








































 I would like to take a moment to thank all of the people who have helped 
and supported me these past years while I have been working towards my Ph.D. 
First and foremost, I would like to thank Dr. Kenneth Byron for accepting me into 
his lab and for his mentorship these past years. The guidance, encouragement, 
and open line of communication that was provided throughout my time at Loyola 
has been instrumental in shaping me into the scientist that I am today. I will always 
be grateful for my training and time spent as a member of the Byron Lab. I would 
also like to thank Dr. Lioubov Brueggemann for her patience, her training, and her 
friendship. I consider myself extremely lucky to have trained under her and to have 
worked alongside her these past years. Outside of training me in the many 
techniques essential for the completion of my project, she has also taught me how 
to laugh at myself and move past setbacks, because “life is never easy”.  
Thank you to my committee members. Dr. Leanne Cribbs, my committee 
chair, has been actively involved in my training at Loyola, both the technical skills 
that I have learned and the leadership skills that I have developed, and I am 
grateful for her mentorship and council. Drs. Tarun Patel and Takeshi Shimamura 
have also been instrumental in the development of my project. Their insightful 
suggestions and the questions they proposed while discussing my project have 
helped me to expand my knowledge and delve deeper into the intricacies of my 
project and proposed aims. I am also thankful for the respiratory physiology 
iv 
 
expertise provided by Dr. Julian Solway. His knowledge has helped me to examine 
the bigger picture surrounding the therapeutic potential of my dissertation work.  
 I am extremely grateful to Loyola University Chicago and the Department of 
Molecular Pharmacology and Therapeutics for the education that I have received 
while pursing my degree and for the many opportunities that I have been given to 
develop my leadership and communication skills at and away from the bench. 
Additionally, I would like to thank the Arthur J. Schmitt Fellowship for providing me 
with pre-doctoral funding for the 2015 academic year, as well as for the drive to 
become a more active member of my community. Thank you to the Veterans 
Affairs for providing the funding for my project, particularly my guinea pig studies, 
through Merit Award I01BX007080. 
 I have been very fortunate to make many friends these past years who have 
been there to help troubleshoot experiments, push me to work harder, and provide 
the support needed to be successful in my endeavors. In particular, Tom Lynch 
and Christina Robakowski have been an invaluable support system both inside 
and outside of Loyola. I would also like to thank Maleen Cabe, Brian Lin, Kristin 
Hicks, Adam Marek, Harold Bach, Kushal Prajapati, Deep Shah, Anne Roessler, 
and Amanda Ward for their friendship and support. 
 Thank you to my friends outside of Loyola, who have become my second 
family, my parents, Craig Haick and Patti Morson, my step-parents, Judi Haick and 
Trevor Morson, and my brother, Ryan Haick, for their continuing love and support. 
Lastly, my fiancé and best friend, James Groner, for his patience and unconditional 






























TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS             iii 
LIST OF TABLES             ix 
LIST OF FIGURES             x 
LIST OF ABBREVIATIONS                      xii 
CHAPTER ONE: INTRODUCTION              1 
CHAPTER TWO: LITERATURE REVIEW             3  
 Airway Smooth Muscle                               3 
 Anatomy and physiology of airway smooth muscle                  3 
Signal transduction in airway smooth muscle cells            3 
     Gq-protein coupled receptor signaling             3 
  Gs-protein coupled receptor signaling              4 
 Protein kinase C in airway smooth muscle             5 
 Regulation of cytosolic Ca2+ in airway smooth muscle           6 
Release of Ca2+ from intracellular stores                   6 
  Mechanisms of Ca2+ influx                     7 
  L-type voltage sensitive Ca2+ channels             8 
 K+ channels in airway smooth muscle           11  
 Asthma                      12   
 Pathophysiology of asthma              12 
  Airway smooth muscle in asthma                  13 
 Asthma therapy                     14  
  Airway inflammation                   14 
  Airway relaxation               15 
  Combination therapy                       16  
  Need for new therapy             17 
 Kv7 Potassium Channels                   18 
 Discovery of Kv7 channels                   19 
 Structure and composition of functional Kv7 channels         20  
 Regulation of Kv7 channels                   22 
 Transcriptional regulation                   22 
Receptor mediated Kv7 current suppression          23  
PIP2 mediated regulation                   23 
  Ca2+/CaM mediated regulation                  24 
 Phosphorylation mediated regulation           24  
 Pharmacology of Kv7 channels                  26 
Expression of Kv7 channels                   28 
Kv7 channels in smooth muscle            29  
Kv7 channels in airway smooth muscle                 30 






CHAPTER THREE: HYPOTHESIS AND AIMS           35 
 
CHAPTER FOUR: MATERIALS AND METHODS          38 
 Cell Culture                     38 
  Adenoviral infection              39 
  Retroviral infection              39 
  Constructs used for infections                      40 
 Electrophysiology                    40  
 Immunoprecipitation and Western Blot Analysis                     41 
 [Ca2+]cyt Measurements with Fura-2                                43 
 Immunofluorescence                              44 
 Mass Spectrometry              45  
  Enzymatic digestion              46 
  High Performance Liquid Chromatography for mass spectrometry        47 
  Liquid Chromatography MS/MS analysis           47 
  Criteria for protein identification            48  
  Post-translation modification site localization           49 
 Animal Welfare and Housing                             50  
 Guinea Pig Sensitization Model            50 
  Tissue collection                  51 
  Precision cut lung slices             51 
 Human Precision Cut Lung Slices            53 
 Guinea Pig flexiVent Optimization Experiments          54 
 Statistics                     55 
 
CHAPTER FIVE: RESULTS             56 
 Cultured HTSMCs Retain SM22α Expression                       56 
 Histamine Increases [Ca2+]cyt in Cultured HTSMCs                              56 
 Activation of PKC Suppresses hKv7.5 Currents in Cultured HTSMCs            58 
 Activation of PKC Induces Phosphorylation of hKv7.5 Channels in       59  
  Cultured HTSMCs    
 PKCα is Necessary for the Regulation of hKv7.5 Currents by Histamine,       62 
  but not for Channel Phosphorylation 
 Threonine Residue 505 may not be Necessary for the Regulation of hKv7.5 63 
  Currents by Histamine 
 Serine Residue 441 is Necessary for Regulation of hKv7.5 Currents by       66  
  Histamine, but not for Channel Phosphorylation 
 Preliminary Mass Spectrometry Results are Inconclusive                67 
 Retigabine Dose-dependently Relaxes Rat Airways Preconstricted with       70  
  Methacholine 
 Formoterol Dose-dependently Relaxes Rat Airways Preconstricted with        74 
  Methacholine 
 Retigabine Enhances Formoterol-induced Relaxation of Rat Airways        75 
  Preconstricted with Methacholine 





  Human Airways Preconstricted with Histamine 
Retigabine Relaxes OVA-sensitized Guinea Pig Airways Preconstricted        78  
  with Methacholine  
 Retigabine Attenuates OVA-induced Allergic Asthma Symptoms in        82  
  OVA-sensitized Guinea Pigs  
 Guinea Pig flexiVent Optimization Experiments and Troubleshooting       85 
 
 
CHAPTER SIX: DISCUSSION AND FUTURE DIRECTIONS         90 
REFERENCE LIST             108 






LIST OF TABLES 
      








LIST OF FIGURES 
 
Figure 1. Schematic of Gq-coupled receptor signaling in ASMCs                  9 
 
Figure 2. Cultured HTSMCs express SM22α through passage 8        57 
    
Figure 3. Histamine induces L-type VSCC-dependent increases in [Ca2+]cyt in  58  
cultured HTSMCs 
 
Figure 4. Histamine inhibits hKv7.5 currents in cultured HTSMCs        60  
 
Figure 5. Histamine-induced inhibition of hKv7.5 currents in cultured HTSMCs 61 
is dependent on PKC 
 
Figure 6. PMA, but not 4α-PMA, inhibits hKv7.5 currents in cultured HTSMCs  63 
 
Figure 7. PKC activation promotes hKv7.5 channel phosphorylation in        64 
HTSMCs 
 
Figure 8. Time course of histamine-induced phosphorylation of hKv7.5          65 
channels in cultured HTSMCs 
 
Figure 9. PKCα is necessary for histamine-induced inhibition of hKv7.5        67 
currents and histamine-induced sustained increases in [Ca2+]cyt  
in cultured HTSMCs 
 
Figure 10. PKCα is not necessary for histamine-induced increases in        69 
hKv7.5 channel phosphorylation in cultured HTSMCs 
 
Figure 11. Threonine 505 may be necessary for histamine-induced inhibition    71 
of hKv7.5 currents in cultured HTSMCs 
 
Figure 12. Serine 441 is necessary for histamine- but not PMA-induced        72 
inhibition of hKv7.5 currents in cultured HTSMCs 
 
Figure 13. Serine 441 is not necessary for histamine- or PMA- induced        73 
phosphorylation of hKv7.5 channels in cultured HTSMCs 
 
Figure 14. Retigabine dose-dependently relaxes rat airways preconstricted      75   
with methacholine 
 







Figure 16. Retigabine enhances formoterol-induced relaxation of rat airways   79 
preconstricted with methacholine 
 
Figure 17. Retigabine attenuates the time-dependent decline in formoterol       80 
induced relaxation of rat airways preconstricted with  
methacholine observed upon repetitive administration 
 
Figure 18. Retigabine appears to attenuate the time-dependent decline in        81 
formoterol-induced relaxation of human airways preconstricted  
with histamine observed upon repetitive administration 
 
Figure 19. Retigabine relaxes control guinea pig airways preconstricted with    83 
methacholine 
 
Figure 20. Retigabine relaxes OVA-sensitized guinea pig airways                  84 
preconstricted with methacholine 
 
Figure 21. Repetitive nebulized methacholine dose response with nebulized    86 
retigabine pretreatment 
 
Figure 22. Repetitive intravenous histamine with increase concentrations of     88 
nebulized retigabine 
 
Figure 23. Nebulized retigabine lowers baseline respiratory resistance       89 
 
Figure 24. Proposed role of Kv7 channels and L-type VSCCs following Gq-      94 














LIST OF ABBREVIATIONS 
 
4α-PMA 4α-Phorbol 12-Myristate 13-Acetate 
AC  Adenylyl Cyclase 
AHR  Airway Hyperresponsiveness 
AKAP  A-kinase Anchoring Protein 
ASMC  Airway Smooth Muscle Cell 
AVP  Arginine8-Vasopressin 
BFNC  Benign Familial Neonatal Convulsions 
BKCa  Large Conductance Calcium-Activated Potassium Channel 
Ca2+  Calcium 
[Ca2+]cyt  Cytosolic Calcium Concentration 
CaM  Calmodulin 
cAMP  Cyclic Adenosine Monophosphate 
CCB  Calcium Channel Blocker 
CPI-17 PKC-Potentiated Inhibitory Protein for Heterotrimeric MLCP of 17 
kDa 
DAG  1,2-diacylglycerol 
DMEM Dulbecco's Modified Eagle's Medium 
DRG  Dorsal Root Ganglia 
EC50  Half-Maximal Effective Concentration 
EndoK Endoproteinase Lys-C 





GFP  Green Fluorescent Protein 
hKv7.5 Human Kv7.5 channels 
HTSMC Human Trachealis Smooth Muscle Cell 
IgE   Immunoglobulin E 
IL-5  Interleukin 5 
IL-13  Interleukin 13 
IP  Immunoprecipitation 
IP3  1,4,5-trisphosphate 
IP3R  1,4,5-trisphosphate Receptor 
i.v.   Intravenous 
I-V  Current-Voltage Relationship 
K+  Potassium 
KATP  ATP-Sensitive Potassium Channel 
KCNQ  Name of Gene Family that Encodes Kv7 Channel Alpha Subunits 
Kv  Voltage-Dependent Delayed Rectifier Potassium Channel 
Kv7  Family of Voltage Gated Ion Changes Encoded by KCNQ Genes 
LABA  Long Acting β2-Agonist 
mHBSS Modified Hank’s Balanced Salt Solution 
mKreb’s Modified Kreb’s Buffer 
mRNA Messenger Ribonucleic Acid 
MLC  Myosin Light Chain 
MLCK  Myosin Light Chain Kinase 





MOI  Multiplicity of Infection 
Na+  Sodium 
NCX  Sodium/Calcium Exchanger 
NH4HCO3 Ammonium Bicarbonate 
PCLS  Precision Cut Lung Slice 
PIP2  Phosphatidylinositol 4,5-Bisphosphate 
PKA  Protein Kinase A 
PKC  Protein Kinase C 
PLC  Phospholipase C 
PMA  Phorbol 12-Myristate 13-Acetate 
PSS  Physiological Saline Solution 
REST  Repressor Element 1-Silencing Transcription Factor 
ROCC Receptor Operated Calcium Channel 
S385  Serine 385 
S441  Serine 441 
S441A Serine 441 Mutated to Alanine 
S752  Serine 752 
S772  Serine 772 
SABA  Short Acting β2-Agonist 
SERCA Sarco/Endoplasmic Reticulum Calcium-ATPase 
shControl Short Hairpin RNA Targeting a Sequence Not Found in the Human 
Genome 





shRNA Short Hairpin Ribonucleic Acid 
SOCC  Store Operated Calcium Channel 
Sp1  Specialty Factor 1 Transcription Factor  
SR  Sarcoplasmic Reticulum 
STIM1 Stromal Interaction Molecule 1 
T505  Threonine 505 
T505A Threonine 505 Mutated to Alanine 
TRP  Transient Receptor Potential 
VSCC  Voltage Sensitive Calcium Channel 
WHO  World Health Organization 
















Asthma is a chronic, heterogeneous disease of the airways in the lung that 
affects 235 million people worldwide and is characterized by inflammation of the 
airways, airway remodeling, and exaggerated narrowing of the airways, termed 
airway hyperresponsiveness (AHR) (WHO 2013, CDC 2014). The 
hypercontraction of airways occurs in response to a variety of stimuli, or triggers, 
such as allergens, cold air, or physical activity. Airway smooth muscle is the 
effector behind the hypercontraction, however the specific role that it plays in the 
pathophysiology of asthma and AHR remain unclear despite extensive study (An, 
Bai et al. 2007). The contractile state of airway smooth muscle is predominantly 
determined by Gq-coupled bronchoconstrictor agonist signaling. These agonists 
include acetylcholine, histamine, endothelin, and leukotriene D4. Activation of Gq-
coupled receptors culminates in an increase in cytosolic calcium [Ca2+] 
concentrations ([Ca2+]cyt) that leads to contraction of airway smooth muscle cells 
(ASMCs) and airway constriction (Penn 2008). Bronchodilator therapy is one type 
of asthma therapy that aims to reverse the airway constriction that results from Gq-
coupled receptor signaling, however there are a limited number of therapeutic 
targets currently available (Pera and Penn 2016). There is also a large population 
of individuals with asthma who have poor control of their disease or develop a 





Chapman, Boulet et al. 2008, Cazzola, Page et al. 2013) indicating the pressing 
need to explore new therapeutic targets for bronchodilator therapy and additional 
treatment options. 
Our lab recently found that Kv7 potassium (K+) channels are expressed in 
airway smooth muscle and that Kv7 currents are inhibited upon treatment with Gq-
coupled bronchoconstrictor agonists in ASMCs. Blockade of Kv7 channels 
resulted in robust constriction of human airways and activation of Kv7 channels 
attenuated airway constriction induced by the bronchoconstrictor agonist 
histamine (Brueggemann, Kakad et al. 2012). Kv7 channels are well-known 
regulators of smooth muscle contractility (Haick and Byron 2016) and are also 
recognized as being downstream of Gq-coupled receptor signaling in a variety of 
tissues (Marrion 1997, Delmas and Brown 2005, Mackie, Brueggemann et al. 
2008). This project aims to elucidate the mechanism of Kv7 K+ channel regulation 
by the bronchoconstrictor histamine in airway smooth muscle and to test the 












Airway Smooth Muscle. 
Anatomy and physiology of airway smooth muscle. Airway smooth 
muscle is located along the posterior aspect of the trachea and encircles airways 
in a helical manner down the bronchial tree. Physiologically, its main purpose is to 
establish and regulate airway diameter and therefore the rate of and resistance to 
airflow, particularly in disease states. When the cells that compose this layer of 
smooth muscle contract, airways constrict, and when the ASMCs relax, airways 
also relax. The narrowing and opening of airways are often a result of signal 
transduction initiated by mediators released from nearby nerves or cells of the 
immune system or epithelium. 
Signal transduction in airway smooth muscle cells. Gq-protein 
coupled receptor signaling. The contractile state of airway smooth muscle is 
largely dictated by the balance of Gs and Gq-coupled receptor signaling, with tone 
being established primarily by procontractile Gq-coupled signaling, with minimal 
input from prorelaxant Gs-coupled receptor signaling in a non-disease state. 
Acetylcholine, a Gq-coupled m3 muscarinic acetylcholine receptor agonist, is 
released from nearby parasympathetic nerves and is the principal mediator of 





promote contraction of ASMCs include histamine, endothelin, and leukotriene D4 
(Penn and Benovic 2008). As depicted in Figure 1, activation of Gq-coupled 
receptors results in the activation of phospholipase C (PLC) which in turn cleaves 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) 
and 1,2-diacylglycerol (DAG). DAG activates protein kinase C (PKC), whose 
effects will be discussed later in this chapter. IP3 binds to the IP3 receptor (IP3R) 
located on the intracellular Ca2+ storage organelle called the sarcoplasmic 
reticulum (SR) and induces Ca2+ release into the intracellular space. The newly 
released Ca2+ binds to calmodulin, forming Ca2+-calmodulin complexes that 
activate myosin light chain (MLC) kinase (MLCK). MLCK phosphorylates MLCs 
which promotes the interaction between actin and myosin, called cross-bridge 
formation, and the cycling between an interacting and non-interacting state, called 
cross-bridge cycling, that causes contraction of the smooth muscle cell (Hall 2000, 
Penn 2008, Penn and Benovic 2008). 
Gs-protein coupled receptor signaling. The counterbalance to 
bronchoconstrictor signaling, and a common target pathway activated by asthma 
therapeutics such as β2-adrenergic agonists, is Gs-coupled receptor signaling. The 
activation of adenylyl cyclase (AC) following Gs-coupled receptor stimulation 
results in the generation of cyclic adenosine monophosphate (cAMP) and the 
subsequent activation of protein kinase A (PKA). PKA phosphorylates IP3Rs, Gq-
coupled receptors, and MLCK resulting in their inhibition, as well as MLC 





actions ultimately result in reduced phosphorylation of MLC and therefore reduced 
actin and myosin cross-bridge cycling and relaxation of the smooth muscle cell. 
Another PKA target is the Ca2+ activated K+ channel, which, when phosphorylated, 
has an increased open probability and therefore promotes membrane 
hyperpolarization and smooth muscle cell relaxation (Hall 2000, Penn 2008, Penn 
and Benovic 2008). 
Protein kinase C in airway smooth muscle. The serine and threonine 
kinase PKC is widely acknowledged as a mediator of bronchoconstriction. Multiple 
isoforms have been observed at the mRNA and protein level in human airway 
smooth muscle. Freshly isolated human trachealis and lung tissues express the 
Ca2+-dependent conventional isoforms α, β1, and β2, Ca2+-independent novel 
isoforms δ, ε, and η, and the atypical isoforms ζ and ι (Webb, Lindsay et al. 1997, 
Sakai, Yamamoto et al. 2009). Cultured human airway smooth muscle cells are 
reported to express all isoforms except γ, although that particular isoform was not 
examined (Carlin, Yang et al. 1999). The PKC isoforms that mediate 
bronchoconstriction have not been specified. 
As described above, the formation of DAG in ASMCs that follows Gq-
coupled receptor activation results in the activation of PKC. PKC acts to 
phosphorylate a number of substrates to promote cross-bridge cycling and ASMC 
contraction, such as MLCP (Webb, Hirst et al. 2000), calponin (Pohl, Winder et al. 
1997), and the PKC-potentiated inhibitory protein for heterotrimeric MLCP of 17 





through phosphorylation of ASMC contractile machinery, there are other PKC-
dependent aspects of ASMC contraction that cannot be explained by these 
mechanisms. Some evidence indicates that PKC-mediated contraction of airway 
smooth muscle is at least partially dependent on extracellular Ca2+ and L-type 
voltage sensitive Ca2+ channel (VSCC) activity (Park and Rasmussen 1985, Knox, 
Baldwin et al. 1993, Rossetti, Savineau et al. 1995, Yang and Black 1996, 
Mukherjee, Trice et al. 2013), signifying a roll for ionic fluxes from the extracellular 
to the intracellular space in airway constriction. 
Regulation of cytosolic Ca2+ in airway smooth muscle. The necessity of 
Ca2+ for ASMC excitation-contraction coupling has been well established and 
multiple participants have been implicated as contributors to the required increase 
in cytosolic Ca2+ concentrations ([Ca2+]cyt). Bronchoconstrictor agonist stimulation 
of ASMCs results in a biphasic increase in [Ca2+]cyt: an initial, transient phase 
mediated primarily by formation of IP3 and release of Ca2+ from intracellular stores 
followed by a sustained, plateau phase dependent on the influx of extracellular 
Ca2+ (Figure 1). 
Release of Ca2+ from intracellular stores in airway smooth muscle 
cells. The initial IP3-mediated increase in [Ca2+]cyt happens within seconds (Hall 
2000) and stimulates a series of Ca2+ oscillations (Hirota, Helli et al. 2007, Jude, 
Wylam et al. 2008) where the newly released Ca2+ activates neighboring IP3Rs 
and thus propagates a wave. IP3Rs are inactivated when Ca2+ interacts with a 





the intracellular space by sarco/endoplasmic reticulum Ca2+-ATPases (SERCA) 
located on the SR membrane or efflux of Ca2+ via sodium (Na+)/Ca2+ exchangers 
(NCXs) and plasma membrane Ca2+-ATPases located on the plasma membrane 
(Perez-Zoghbi, Karner et al. 2009). Ryanodine receptors have also been 
implicated in contributing to Ca2+ release from internal stores and participating in 
the Ca2+ oscillations (An, Bai et al. 2007, Hirota, Helli et al. 2007). 
Mechanisms of Ca2+ influx in airway smooth muscle cells. An influx of 
extracellular Ca2+ is necessary to maintain the increase in [Ca2+]cyt and for 
sustained ASMC contraction. Although there is still disagreement as to the 
predominant mechanism of this Ca2+ influx, largely due to differences observed 
between species or bronchoconstrictor agonists, evidence suggests that there are 
voltage-independent and voltage-dependent components. Entry of Ca2+ through 
store operated Ca2+ channels (SOCCs), likely involving the Ca2+ store depletion 
sensor stromal interaction molecule 1 (STIM1) (Peel, Liu et al. 2006) and the Ca2+ 
release-activated Ca2+ channel protein Orai 1 (Peel, Liu et al. 2008), is one voltage-
independent mechanism that has been implicated in Ca2+ influx in ASMCs. 
Receptor operated Ca2+ channels (ROCCs) have also been indicated as a 
mechanism of Ca2+ influx. Transient receptor potential (TRP) channels have been 
indicated as both SOCCs and ROCCs (Gosling, Poll et al. 2005, Perez-Zoghbi, 
Karner et al. 2009, Wang and Zheng 2011). Lastly, the NCX is thought to switch 
to reverse mode upon an accumulation of Na+ in the intracellular space and/or a 





et al. 2007). The voltage-dependent element of Ca2+ influx is evidenced to occur 
through L-type VSCCs. 
L-type voltage sensitive Ca2+ channels in airway smooth muscle cells. 
L-type VSCC currents have been identified in ASMCs from multiple species 
(Hirota, Helli et al. 2007), including human (Marthan, Cecile et al. 1989, Worley 
and Kotlikoff 1990). Their role in vascular smooth muscle cell contraction is well 
understood, however the debate over their importance in ASMC contraction wages 
on. L-type VSCCs are activated by membrane depolarization. More specifically, 
the channels activate when membrane voltages reach -45 to -25 millivolts (mV), 
are maximally active at 0 to +20 mV, and are blocked by dihydropyridines,  
phenylalkylamines, or inorganic cations (Hirota, Helli et al. 2007). 
Bronchoconstrictor agonists induce ASMC membrane depolarization (Janssen 
and Killian 2006, Hirota, Helli et al. 2007, Byron, Brueggemann et al. 2014, Haick, 
Brueggemann et al. 2017) and in many instances L-type VSCC blockers have 
been shown to reverse the effects of bronchoconstrictors, such as Ca2+ influx 
(Flores-Soto, Reyes-Garcia et al. 2013) and ASMC contraction (Kamishima, 
Nelson et al. 1992, Watts, Cox et al. 1994, Dai, Kuo et al. 2007, Hirota and Janssen 
2007). Although there is some evidence of a lesser role for L-type VSCCs in Ca2+ 
influx in ASMCs (Murray and Kotlikoff 1991, Janssen 2002, Janssen and Killian 
2006), there is clinical evidence that offers support for their role in the regulation 








Figure 1. Schematic of Gq-coupled receptor signaling in ASMCs. Activation of 
Gq-coupled receptors by bronchoconstrictor agonists (such as histamine, 
acetylcholine, endothelin, leukotriene D4) results in the activation of phospholipase 
C (PLC), the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 binds to the IP3 
receptor located on the sarcoplasmic reticulum (SR), promoting Ca2+ release into 
the intracellular space. This is the initial transient phase of increased cytosolic 
Ca2+. Sustained contraction of ASMCs requires an influx of Ca2+ from the 
extracellular space. This occurs through receptor operated Ca2+ channels 
(ROCCs), store operated Ca2+ channels (SOCCs), L-type voltage sensitive Ca2+ 
channels (VSCCs) and reversal of the Na+/Ca2+ exchanger. Ca2+ binds to 
calmodulin (CaM), forming the Ca2+/CaM complex and activates myosin light chain 
kinase (MLCK). MLCK phosphorylates myosin light chains and promotes actin and 
myosin cross-bridge formation and ASMC contraction. 
 
 
In the 1980’s, the calcium channel blockers (CCBs) nifedipine and 
verapamil underwent numerous clinical trials for the treatment of asthma with 





protection. Overall, they have been deemed an ineffective treatment despite the 
fact that many studies contained at least a subset of asthmatic patients that 
benefited from CCB treatment (Fish 1984, Barnes 1985, Fanta 1985, Solway and 
Fanta 1985). Although it is important to acknowledge evidence on both sides of 
the controversy, there are certain considerations to be made for re-evaluating the 
potential of L-type VSCCs as therapeutic targets for asthma. Multiple studies have 
indicated that the effectiveness of CCBs appears to be dependent on 
bronchoconstrictor agonist concentration or the extent of bronchial provocation. At 
low concentrations of the bronchoconstrictor methacholine, rat airway constriction 
was reversed upon treatment with the VSCC blocker verapamil, however this was 
not the case when airways were exposed to high concentrations of methacholine 
(Byron, Brueggemann et al. 2014). A similar bronchoconstrictor concentration-
dependence was observed for verapamil-induced relaxation of acetylcholine-
induced contraction of canine trachealis; verapamil attenuated agonist-induced 
contraction of the smooth muscle, but only at low acetylcholine doses (Farley and 
Miles 1978). In human trials, oral nifedipine was only effective at attenuating 
isocapnic hyperventilation of cold air at lower and intermediate minute ventilation 
rates (Solway and Fanta 1985). These results suggest that there are different 
sources of Ca2+, perhaps a voltage-dependent source with submaximal stimulus 
versus voltage-independent source with maximum stimulus, for ASMC contraction. 
Other considerations include the fact that cardiovascular side-effects have limited 





development (Fish 1984, Barnes 1985, Solway and Fanta 1985). Despite the fact 
that clinical trials using CCBs were largely deemed unsuccessful, targeting 
different players in this pathway remains a viable option for the treatment of asthma 
and should be explored. 
K+ channels in airway smooth muscle. The resting membrane potential 
of human ASMCs ranges from -45 to -60 mV and oscillates in slow waves, however 
the oscillations rarely result in the generation of spontaneous action potentials due 
to the strong outward rectification of K+ through K+ channels that promotes 
membrane hyperpolarization (Thirstrup 2000). Inhibition of the outward K+ currents 
results in the induction of action potentials (Marthan, Cecile et al. 1989). One family 
of K+ efflux mediators found in ASMCs, and the most important in terms of 
membrane potential regulation, are voltage-dependent delayed rectifier K+ (Kv) 
channels (Kotlikoff 1990, Boyle, Tomasic et al. 1992, Fleischmann, Washabau et 
al. 1993, Hall 2000, An, Bai et al. 2007, Hirota, Helli et al. 2007). Large 
conductance Ca2+-activated K+ (BKCa) channels, whose hyperpolarizing currents 
are involved in β2-agonist mediated airway relaxation (Kume, Hall et al. 1994), and 
ATP-sensitive K+ (KATP) channels, believed to have little, if any, impact on ASMC 
contraction or relaxation, are also expressed in ASMCs (Hall 2000, Liu and Xu 
2005, Hirota, Helli et al. 2007). 
Different subtypes of Kv channels have been found to be expressed in 
ASMCs. Kv1.2, Kv1.5, and Kv1.1 channels have been detected at the mRNA level 





al. 1996) while Kv7.1, Kv7.4, and Kv7.5 channels have been detected at the mRNA 
level in freshly isolated human trachealis smooth muscle (Brueggemann, Kakad et 
al. 2012). Some evidence exists that Kv currents in rat and human ASMCs are 
inhibited upon activation of PKC (Liu, Xu et al. 2003, Cheng, Xu et al. 2007), and 
Kv7 currents in freshly isolated guinea pig ASMCs are inhibited following treatment 
with bronchoconstrictor agonists (Brueggemann, Kakad et al. 2012). However, the 
specific mechanism(s) behind this current inhibition or how to exploit this 
knowledge for a therapeutic benefit have yet to be explored. 
 
Asthma. 
Pathophysiology of asthma. Asthma is a chronic disease of the airways 
that affects an estimated 235 million people worldwide (WHO 2013). In the United 
States specifically, more than 25 million people have asthma, with 7 million of 
those cases affecting children (CDC 2014). Asthma is characterized by reversible, 
exaggerated obstruction to airflow that results from a combination of AHR, chronic 
airway inflammation, increased mucus production, and airway remodeling that 
ultimately results in the thickening of airway walls (Fanta 2009, Kudo, Ishigatsubo 
et al. 2013, Olin and Wechsler 2014). To briefly summarize an extensive and 
complicated aspect of the disease, the chronic airway inflammation results from 
an increased infiltration of immune cells, such as mast cells, eosinophils, and T 
cells. These immune cells release mediators, such as cytokines and 





remodeling (Hamid and Tulic 2009). The remodeling is principally an expansion of 
non-smooth muscle connective tissue and smooth muscle, as well as an increase 
in the number of mucus glands. The structural changes, such as increased airway 
smooth muscle mass and fibrosis below the epithelium, associated with airway 
remodeling are often a consequence of the tissue damage that results from chronic 
inflammation and inflammatory mediator release (Homer and Elias 2005). 
Airway smooth muscle in asthma. Airway smooth muscle is known to 
have multiple roles in the asthmatic disease state. Hyperplasia and hypertrophy of 
ASMCs are linked to the increased airway smooth muscle mass associated with 
airway remodeling (Homer and Elias 2005, Prakash 2013). ASMCs also secrete a 
variety of factors, including cytokines that affect the inflammatory state of 
surrounding tissue and molecules that participate in growth and remodeling (Xia, 
Redhu et al. 2013). Airway smooth muscle is most well known as the contractile 
effector of the hyperresponsiveness associated with asthma. A hallmark of 
asthma, AHR is the nonspecific, exaggerated constriction of airway smooth muscle 
in response to stimuli such as bronchoconstrictor agonists, cold air, or exercise. 
AHR is attributed to an increase in sensitivity of asthmatic airways, however the 
extent to which functional, structural, or molecular properties of airway smooth 
muscle contributes to the increased sensitivity remains unclear (An, Bai et al. 2007, 







Asthma therapy. Airway inflammation. One important goal of asthma 
therapy is to reduce and prevent, or even eliminate, the inflammation associated 
with the disease. Corticosteroids are the most frequently used therapeutic option 
to manage airway inflammation. Briefly, the glucocorticoid binds to its receptor in 
the cytosol and the newly formed complex translocates to the nucleus where it 
dimerizes with another glucocorticoid-receptor complex, binds to the glucocorticoid 
response element on the promoter region of specific DNA sequences, and exerts 
its effects through regulation of gene transcription. Examples of these inflammatory 
suppressive effects include decreased cytokine and inflammatory mediator 
production and increased anti-inflammatory mediator production (Umland, 
Schleimer et al. 2002). 
Although corticosteroids are considered to be the most efficacious form of 
anti-inflammatory therapy for asthma, they do not suppress all inflammatory 
responses – including leukotriene production. Leukotrienes are inflammatory 
mediators that participate in the pathogenesis of asthma by acting as 
chemoattractants, promoting mucus secretion, and inducing airway smooth 
muscle proliferation. Cysteinyl conjugate leukotrienes also act as potent 
bronchoconstrictors. Leukotriene modifiers are another class of anti-inflammatory 
asthma therapeutics that act to either inhibit the synthesis of leukotrienes or 
antagonize their actions at leukotriene receptors (Salvi, Krishna et al. 2001). 
In cases of severe allergic asthma or corticosteroid-resistant asthma, anti-





anti-IgE antibodies bind to serum IgE and prevent IgE from binding to its receptor 
located on effector cells, such as mast cells and basophils, thus averting the 
cellular response to allergens that manifests in asthmatic symptoms, such as 
inflammation and allergen-induced bronchoconstriction (D'Amato, Stanziola et al. 
2014). Targeting specific inflammatory agents to modify the immunologic 
responses associated with cytokine cell signaling is one of the new approaches 
being undertaken to better control asthmatic symptoms. Antibodies against IL-5 
and IL-13 are two examples of potential treatment options that have undergone 
clinical trials with promising results (Olin and Wechsler 2014, Pera and Penn 
2016). 
Airway relaxation. Another essential goal of asthma therapy is to prevent 
or attenuate the exaggerated airway constriction associated with the disease. The 
most common targets for bronchodilator therapy are the G-protein coupled 
receptors located on airway smooth muscle that are involved in the regulation of 
its contractile state. Opposing the downstream effects of Gq-coupled agonists by 
activating the Gs-coupled receptor pathway is one method to promote airway 
relaxation (Pera and Penn 2016). The β2-adrenergic receptor has been the primary 
target of bronchodilator therapy for decades. The initial β2-agonists exhibited a 
short duration of action, now referred to as short acting β2-agonists (SABAs), and 
are currently used as “rescue” medications for acute asthma attacks. Long acting 
β2-agonists (LABAs) were developed with the purpose of extending the duration of 





(Cazzola, Page et al. 2013). Other Gs-coupled receptors that relax airway smooth 
muscle when activated include bitter taste receptors, which promote ASMC 
relaxation via activation of BKCa channels, and prostaglandin E2 receptors, which 
exert their actions via traditional Gs-protein coupled receptor signaling. The 
development of therapeutic agonists for these receptors, however, has yet to be 
completed (Dowell, Lavoie et al. 2014). 
Antagonizing Gq-coupled muscarinic receptors is another therapeutic 
approach currently utilized to relax airways, particularly when corticosteroid and 
LABA therapy is insufficient for symptom management. By competing with 
acetylcholine for the muscarinic receptors, muscarinic antagonists promote 
bronchodilation and also have the potential to attenuate acetylcholine-induced 
inflammation and mucus secretion that contribute to the pathophysiology of 
asthma (Busse, Dahl et al. 2016, D'Amato, Vitale et al. 2017). 
Combination therapy. Seeing as there are multiple components that 
contribute to the pathology of asthma, such as inflammation and excessive 
bronchoconstriction, a combination of therapeutic approaches is necessary to 
manage the disease symptoms. The most commonly prescribed therapy is the 
combination of a LABA and an inhaled corticosteroid (Cazzola, Page et al. 2013, 
Ricciardolo, Blasi et al. 2015). There are also new studies that indicate the 
beneficial effects of combining a LABA with a long-acting muscarinic receptor 
antagonist (Ricciardolo, Blasi et al. 2015), introducing the possibility of a more 





Need for new therapy. Mainstream asthma therapy has remained 
relatively constant over the past few decades. Some enhancements have been 
made to improve the duration or specificity of current treatment options, however 
the most common courses of action have not changed. Despite the improvements 
made and the continued research into new asthma therapeutics, it has been 
reported in some studies that greater than 50% of the asthmatic population have 
poor control over their symptoms (Peters, Jones et al. 2007, Chapman, Boulet et 
al. 2008). Inadequately controlled asthma leads to not only a poorer quality of life 
for the patient but also an increased financial burden on the patient and healthcare 
system (Busse, Dahl et al. 2016). One cause of the poor symptom management is 
the tolerance, or tachyphylaxis, that develops upon extended used of β2-agonists. 
This manifests as decreased sensitivity to bronchodilator therapy that is believed 
to occur as a result of desensitization of the β2-receptor (Cazzola, Page et al. 2013, 
Pera and Penn 2016). There is also a portion of the asthmatic population that does 
not benefit from the standard inhaled corticosteroid therapy. Many of these patients 
attempt to control their asthma with high doses of oral corticosteroid therapy, 
however the high dose and delivery method make the patients more prone to the 
negative side effects of treatment (Ricciardolo, Blasi et al. 2015, Pera and Penn 
2016). 
It is clear that new therapeutic options must be explored to meet the 
pressing need for additional asthma treatment options. The prevalence of asthma 





poorly managed disease symptoms. The research presented in this dissertation 
suggests that targeting Kv7 K+ channels with channel activators may be a novel 
and efficacious approach to asthma therapy, potentially meeting the currently 
unmet need. 
 
Kv7 Potassium Channels. 
 Kv7 K+ channels were named by the International Union of Pharmacology 
based on the phylogenetic relationships established for Kv1-Kv9 channels. There 
are five subtypes, Kv7.1-Kv7.5, whose five gene names, KCNQ1-KCNQ5, were 
established by the Human Genome Organization Nomenclature Committee 
(Gutman, Chandy et al. 2005). The Kv7 and KCNQ nomenclature are used 
interchangeably when discussing the channel protein.  
The outwardly rectifying K+ currents conducted by Kv7 channels have three 
distinct biophysical properties (Marrion 1997). (1) The threshold of activation of 
Kv7 current is approximately -60 mV, which is similar to the resting membrane 
potential of excitable cells such as neurons, (2) the current produced following 
membrane depolarization is enhanced in a slow and voltage-dependent manner, 
and (3) the current does not inactivate. These properties make Kv7 channels 
uniquely qualified to set and maintain the resting membrane potential of neurons 
and other excitable cells. Additional channel activation that occurs as a result of 
membrane depolarization opposes additional depolarization while promoting 





if these channels are no longer able to function, either due to mutation or inhibition, 
the membrane potential would be expected to trend more positive, leading to 
increased firing of action potentials.  
Discovery of Kv7 channels. The Kv7.1 subtype, the first of the Kv7 
channel family to be identified, was initially discovered in the heart (Sanguinetti, 
Curran et al. 1996). Kv7.1 α-subunits form a homotetramer that, with the aid of two 
auxiliary subunits (see structure and composition of functional channels section 
below), mediate the slow delayed rectifier current IKS, which contributes to the 
repolarization of the cardiac action potential (Barhanin, Lesage et al. 1996, 
Sanguinetti, Curran et al. 1996).  
“M-currents” were first isolated in frog sympathetic neurons nearly four 
decades ago (Brown and Adams 1980). This outwardly rectifying K+ current, 
named after their suppression following the activation of muscarinic receptors 
(Kobayashi and Libet 1968, Weight and Votava 1970, Krnjevic, Pumain et al. 
1971), is slow to activate, does so in a voltage-sensitive manner, and exhibits little, 
if any, inactivation during sustained membrane depolarizations. Due to the 
negative threshold of activation, approximately -60 mV, these currents promote the 
stabilization of the negative membrane voltage in neurons and act to suppress 
neuronal excitability (Brown and Adams 1980). It wasn’t until the late 1990’s that 
the gene products responsible for producing the M-current were identified. When 
messenger RNAs encoding human KCNQ2 (Kv7.2) and rat KCNQ3 (Kv7.3) were 





current observed in neurons. Similar to endogenous M-currents in sympathetic 
neurons, these exogenous currents were sensitive to the Kv7 channel blockers 
linopirdine and XE991, providing additional evidence for the identification of the K+ 
channel family behind the M-current (Wang, Pan et al. 1998). 
Structure and composition of functional Kv7 channels. Functional Kv7 
channels are formed homo- or heterotetramers of α-subunits. Each α-subunit has 
six transmembrane domains (S1-S6) that contain a voltage sensor domain (S4) 
and a single pore loop between the S5-S6 domains that acts as a selectivity filter 
when the four subunits are assembled (Jentsch 2000). Both the amino and carboxy 
termini of each Kv7 subunit are intracellular. The amino terminus is evidenced to 
be involved in the localization of Kv7.1 channels to the membrane and it is believed 
to play a role in the open probability of Kv7.2/Kv7.3 channels (Choveau and 
Shapiro 2012). More comprehensive studies have taken place examining the 
different aspects of the long carboxy termini of Kv7 channels, which are comprised 
of four helical regions, A-D. Helices A and B are primarily recognized for their 
critical interaction with calmodulin (CaM) (Yus-Najera, Santana-Castro et al. 2002, 
Haitin and Attali 2008), while the coiled-coil domains, helices C and D, are believed 
to be responsible for determining the subunit specificity of channel assembly 
(Schwake, Jentsch et al. 2003, Schwake, Athanasiadu et al. 2006, Haitin and Attali 
2008). There are also regions of the C-terminus that are critical for channel 
trafficking, assembly, cell surface expression, and gating (Haitin and Attali 2008) 





proteins (AKAPs) (Hoshi, Zhang et al. 2003, Haitin and Attali 2008). The C-
terminus also contains amino acid residues that are phosphorylated by a variety 
of kinases, such as PKC (Hoshi, Zhang et al. 2003) and Src tyrosine kinase 
(Gamper, Stockand et al. 2003), that have the potential to modify channel function.  
All five Kv7 subtypes are able to form homotetramers, however 
heteromization is limited to specific combinations. Kv7.1 does not co-assemble 
with any other channel subtype. Co-expression studies have revealed that Kv7.3 
and Kv7.2 can form functional heteromers (Wang, Pan et al. 1998), Kv7.4 
heteromizes with Kv7.3 (Kubisch, Schroeder et al. 1999), and Kv7.5 can co-
assemble with Kv7.3 (Schroeder, Hechenberger et al. 2000) and Kv7.4 (Bal, 
Zhang et al. 2008, Brueggemann, Mackie et al. 2014, Chadha, Jepps et al. 2014). 
Auxiliary β-subunits are often important determinants of the expression and 
function of Kv channels (Brueggemann, Gentile et al. 2013). With regard to Kv7 
channels, there is considerable evidence that KCNE1 (also called minK) and 
KCNE2-5 (or minK-related peptides), can associate with and regulate channel 
expression and function. KCNE1 is the best studied due to its partnership with 
Kv7.1 to mediate IKS in cardiac myocytes. Two KCNE1 subunits are thought to 
associate with a homotetramer of Kv7.1 α-subunits to form functional channels that 
give rise to the slowly activating IKs current (Morin and Kobertz 2008). The 
presence of KCNE1 is responsible for the slow channel activation (Sanguinetti, 
Curran et al. 1996) and it also increases channel conductance (Pusch 1998). 





modulating Kv7 channel expression and function in tissues other than the heart, 
but KCNE subtypes have been found to modulate the function of Kv7 channel 
subtypes in expression systems. For example, KCNE2 decreases Kv7.1 current 
density (Tinel, Diochot et al. 2000) and KCNE3 greatly enhances Kv7.1 current 
density (Bendahhou, Marionneau et al. 2005), while KCNE4 and 5 both suppress 
Kv7.1 currents (Angelo, Jespersen et al. 2002, Grunnet, Jespersen et al. 2002, 
Grunnet, Olesen et al. 2005). KCNE1 enhances Kv7.5 currents while slowing their 
activation (Roura-Ferrer, Etxebarria et al. 2009), KCNE2 accelerates the activation 
and deactivation kinetics of Kv7.2/3 currents (Tinel, Diochot et al. 2000), KCNE3 
suppresses Kv7.4 (Schroeder, Hechenberger et al. 2000) and Kv7.5 (Roura-
Ferrer, Etxebarria et al. 2009) currents, whereas KCNE4 increases Kv7.4 current 
amplitude (Strutz-Seebohm, Seebohm et al. 2006, Jepps, Carr et al. 2015). 
Regulation of Kv7 channels. Transcriptional regulation. Although the 
functional importance of Kv7 channels in a variety of tissues is acknowledged and 
continues to be an area of intense study, little is known about the mechanisms 
governing transcriptional regulation of the channels. Expression of KCNQ2 and 
KCNQ3 genes is activated by the specialty factor 1 (sp1) in dorsal root ganglia 
(DRG) neurons (Mucha, Ooi et al. 2010), however little else is known in regards to 
transcriptional activation of KCNQ genes. A slightly more widespread research 
effort has been put into examining repression of KCNQ gene expression by 
repressor element 1-silencing transcription factor (REST), a transcriptional 





binding sites for REST are present in KCNQ2, KCNQ3, KCNQ5 (Mucha, Ooi et al. 
2010), and KCNQ4 (Iannotti, Barrese et al. 2013) genes. Treatment of DRG 
neurons with inflammatory mediators (Mucha, Ooi et al. 2010) and a neuropathic 
injury rat model (Rose, Ooi et al. 2011) demonstrated an increase in REST 
expression that correlated with a decrease in Kv7.2 expression. These 
observations have led to the hypothesis that REST-induced Kv7.2 downregulation 
may be a mechanism that contributes to neuronal over-excitability associated with 
neuropathic pain. 
Receptor mediated Kv7 current suppression. The suppression of Kv7 
currents following activation of a variety of Gq-coupled receptors has been widely 
studied ever since the first instance of M-current inhibition was observed in 1980 
(Brown and Adams 1980). Stimulation of Gq-coupled receptors found in neurons 
(Marrion 1997, Delmas and Brown 2005), vascular smooth muscle cells (Mackie, 
Brueggemann et al. 2008, Mani, O'Dowd et al. 2013), and ASMCs (Brueggemann, 
Kakad et al. 2012, Evseev, Semenov et al. 2013, Brueggemann, Haick et al. 2014) 
results in Kv7 current inhibition.  
PIP2 mediated regulation. One consequence of Gq-coupled receptor 
activation is the activation of PLC and subsequent hydrolysis of PIP2 to IP3 and 
DAG. Once it was established that PIP2 depletion was the mechanism for M-
current inhibition following muscarinic receptor activation (Suh and Hille 2002), 
numerous studies have examined the necessity of PIP2 for Kv7 channels to remain 





including investigations of the correlation between a channel’s affinity for PIP2 
being related to its open probability (Li, Gamper et al. 2005).  
Ca2+/CaM mediated regulation. Receptor-mediated inhibition of Kv7 
currents can also be mediated by Ca2+/CaM, as is the case for M-current 
suppression by the hormone bradykinin. The mechanism of M-current inhibition by 
bradykinin differs from that of muscarinic receptor-mediated M-current inhibition in 
that it is dependent on IP3-mediated Ca2+ release from intracellular stores 
(Cruzblanca, Koh et al. 1998). Ca2+ was found to inhibit M-currents with an IC50 of 
approximately 100 nM (Selyanko and Brown 1996), a sensitivity that is dependent 
on the presence of CaM acting as a Ca2+ sensor (Gamper and Shapiro 2003).   
Phosphorylation mediated regulation. Another consequence of Gq-
coupled receptor activation is the activation of the serine/threonine kinase PKC. 
Past experiments investigating the inhibition of M-currents by phorbol esters, which 
directly activate PKC, and PKC inhibitors have yielded variable results (Marrion 
1997). The study completed by Hoshi et al. (2003) was pivotal in terms of beginning 
to clarify the role of PKC in Kv7 current regulation. AKAP interacts with PKC and 
Kv7 channels, among other proteins, to form a signalosome and facilitate signal 
transduction. PKC-induced phosphorylation of Kv7.2 channels was attenuated 
upon expression of a mutated AKAP that was unable to bind PKC (Hoshi, Zhang 
et al. 2003). Since then, AKAP has been deemed necessary for M-current 
inhibition following muscarinic receptor stimulation in mice (Tunquist, Hoshi et al. 





all Kv7 subtypes save for Kv7.1. The interaction between AKAP and Kv7 channels 
acts to “sensitize” the channels to muscarinic inhibition (Bal, Zhang et al. 2010). 
The role of PKC in Kv7 current regulation is also evident in vascular smooth 
muscle. The suppression of native Kv7 currents following treatment with the Gq-
coupled receptor agonist arginine8-vasopressin (AVP) was found to be dependent 
on the activation of PKC in cultured A7r5 rat aortic smooth muscle cells, that 
express Kv7.5 homomeric channels, and freshly isolated rat mesenteric artery 
smooth muscle cells, that express Kv7.4/Kv7.5 heteromeric channels 
(Brueggemann, Moran et al. 2007, Mackie, Brueggemann et al. 2008, 
Brueggemann, Mackie et al. 2014). Treatment of A7r5 cells with AVP resulted in a 
PKC-dependent increase in channel phosphorylation of overexpressed Kv7.5, but 
not Kv7.4, channels (Brueggemann, Mackie et al. 2014).  
 Members of the Src family of non-receptor tyrosine kinases are known to 
phosphorylate Kv7 channels, resulting in Kv7 current inhibition. Src 
phosphorylates Kv7.3, Kv7.4, and Kv7.5 homomeric channels, but not Kv7.1 or 
Kv7.2 homomers. This phosphorylation correlates with subunit-specific current 
inhibition and slowing of channel activation kinetics (Gamper, Stockand et al. 
2003). Native M-currents, produced by Kv7.2/Kv7.3 heterotetramers, were also 
suppressed by Src overexpression in rat sympathetic neurons (Gamper, Stockand 
et al. 2003), implying the functional importance of Kv7.3 phosphorylation by Src. 
Tyrosine residues 67 and 349, located on the amino and carboxy termini of Kv7.3, 





Langlais et al. 2004). The physiological relevance of this channel regulation by Src 
remains to be determined. 
 PKA is yet another kinase that has been implicated in the regulation of Kv7 
currents. Activation of the β-adrenergic receptor/cAMP/PKA pathway increased 
Kv7.1 current amplitude in cardiomyocytes (Chen and Kass 2011). Kv7.2/Kv7.3 
heteromeric currents were enhanced by PKA and Kv7.2 serine 52 was 
phosphorylated in a PKA dependent manner in overexpression systems, 
(Schroeder, Kubisch et al. 1998) however no association to endogenous M-current 
regulation has been established. Application of the PKA catalytic subunit enhanced 
Kv7.4 currents, (Chambard and Ashmore 2005) although a link between the PKA-
dependent regulation of Kv7.4 channels and signaling events that occur in 
cochlear outer hair cells have yet to be established. The Gs-coupled receptor 
agonist isoproterenol enhanced Kv7.5 homomeric currents, both endogenous and 
exogenous, in a PKA-dependent manner in A7r5 rat aortic smooth muscle cells. 
Isoproterenol enhanced exogenous Kv7.4/Kv7.5 heteromeric currents to a lesser 
extent and had no effect on exogenous Kv7.4 homomeric currents (Mani, 
Robakowski et al. 2016). Additional research examining the physiological 
relevance of PKA-induced enhancement of Kv7 currents is necessary when 
considering the possibility of exploiting this mechanism for therapeutic benefit in a 
variety of tissues. 
Pharmacology of Kv7 channels. The presence and function of Kv7 





development of pharmacological agents that selectively block or activate these 
channels. Linopirdine (1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol-
2-one) was initially observed to be an enhancer of depolarization-induced 
neurotransmitter release and ultimately found to do so via its inhibitory actions on 
M-currents (Aiken, Lampe et al. 1995). Both linopirdine, and it’s more potent 
analog XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone), are the most 
widely used experimental Kv7 channel blockers, effectively block all five Kv7 
subtypes, and are largely specific for Kv7 channels at concentrations up to 10 µM 
(Schnee and Brown 1998, Wang, Pan et al. 1998, Wang, Brown et al. 2000, 
Wladyka and Kunze 2006). Chromanol 293B 
 (trans-N-[6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-
methyl-ethanesulfonamide) (Busch, Suessbrich et al. 1996, Bleich, Briel et al. 
1997) and HMR-1556 (N-[3-Hydroxy-2,2-dimethyl-6-(4,4,4-trifluoro-butoxy)-
chroman-4-yl]-N-methyl-methanesulfonamide) (Thomas, Gerlach et al. 2003) are 
reported to be specific blockers of the Kv7.1 channel subtype. 
 The Kv7 channel pharmacological toolbox also contains a variety of channel 
activators. Flupirtine ([2-Amino-6-[[(4-fluorophenyl)methyl]amino]-3-
pyridinyl]carbamic acid ethyl ester) and retigabine (N-(2-Amino-4-(4-
fluorobenzylamino)phenyl)carbamic acid ethyl ester) are the most frequently used 
Kv7 channel activators. These drugs activate only Kv7.2-Kv7.5 channels; the 
Kv7.1 subtype lacks a critical tryptophan residue required for activation by either 





364373 (also known as R-L3; 5-(2-Fluorophenyl)-1,3-dihydro-3-(1H-indol-3-
ylmethyl)-1-methyl-2H-1,4-benzodiazepin-2-one) is reported to activate only Kv7.1 
channels (Salata, Jurkiewicz et al. 1998, Seebohm, Pusch et al. 2003). Other Kv7 
activators include ICA-27243 (N-(6-chloropyridin-3-yl)-3,4-difluorobenzamide), a 
more effective activator of Kv7.2/Kv7.3 heterotetramers compared to Kv7.1, Kv7.3 
or Kv7.4 homotetramers and Kv7.3/Kv7.5 heterotetramers (Wickenden, Krajewski 
et al. 2008, Padilla, Wickenden et al. 2009), and its analog, ICA-069673 (N-(2-
Chloro-5-pyrimidinyl)-3,4-difluorobenzamide), an activator that enhanced Kv7.4 
homotetramer currents to a greater extent than Kv7.5 homotetramer currents 
(Brueggemann, Haick et al. 2014). Diclofenac (2-[2-(2,6-
dichloroanilino)phenyl]acetic acid) is unique in that it was found to enhance 
currents from Kv7.4 homotetramers but block currents from Kv7.5 homotetramers, 
with only moderate inhibition of currents Kv7.4/Kv7.5 heterotetramers 
(Brueggemann, Mackie et al. 2011). 
Expression of Kv7 channels. Cardiomyocytes express Kv7.1 
homotetramers that, with the help of KCNE1 β-subunits, mediate IKS (Barhanin, 
Lesage et al. 1996, Sanguinetti, Curran et al. 1996). Mutations in Kv7.1 often result 
in a cardiac condition called long QT syndrome where delayed repolarization of 
the cardiac action potential can cause potentially fatal cardiac arrhythmias (Chiang 
and Roden 2000). In neurons, Kv7.2 and Kv7.3 are the predominant Kv7 subtypes 
expressed and they form heterotetramers responsible for the M-current, although 





and Kv7.3 channels cause a reduction of M-current and result in a neonatal form 
of epilepsy called benign familial neonatal convulsions (BFNC) (Biervert, 
Schroeder et al. 1998, Singh, Charlier et al. 1998, Jentsch 2000). Kv7.4 channels 
mediate IKN, a Kv current that opposes the excitability of the specialized sensory 
neurons in the sensory outer hair cells of the cochlea. Mutations in Kv7.4 result in 
an autosomal dominant progressive deafness that results from eventual 
degradation of the sensory hair cells (Kubisch, Schroeder et al. 1999, Kharkovets, 
Hardelin et al. 2000). Multiple Kv7 subtypes are expressed in skeletal muscle cells 
(Iannotti, Panza et al. 2010) and Kv7.5 in particular has been implicated in the 
regulation of the proliferation and differentiation of myoblasts (Roura-Ferrer, Sole 
et al. 2008). Functional Kv7 channels have also been discovered in a wide variety 
of smooth muscle tissues (see Kv7 channels in smooth muscle and Kv7 channels 
in airway smooth muscle sections below).  
Kv7 channels in smooth muscle. Kv7 channels are expressed in a variety 
of different types of smooth muscle (Greenwood and Ohya 2009, Jepps, Olesen 
et al. 2013, Stott, Jepps et al. 2014, Haick and Byron 2016). Smooth muscle 
located in the gastrointestinal tract (Ohya, Asakura et al. 2002, Jepps, Greenwood 
et al. 2009, Ipavec, Martire et al. 2011, Adduci, Martire et al. 2013), bladder (Rode, 
Svalo et al. 2010, Svalo, Hansen et al. 2012, Afeli, Malysz et al. 2013, Anderson, 
Carson et al. 2013, Svalo, Bille et al. 2013, Provence, Hristov et al. 2015, Svalo, 
Sheykhzade et al. 2015), and myometrium (Aaronson, Sarwar et al. 2006, 





species express Kv7 channels that regulate the contractile state of the smooth 
muscle they are located in; treatment of tissue preparations with Kv7 channel 
inhibitors induces contraction of visceral smooth muscle while treatment with Kv7 
channel activators relaxes visceral smooth muscle.  
The expression of Kv7 channels has also been observed in a variety of 
vascular smooth muscle beds in mice (Ohya, Asakura et al. 2002, Ohya, Sergeant 
et al. 2003, Yeung, Pucovsky et al. 2007, Yeung, Schwake et al. 2008, Lee, Yang 
et al. 2015), rats (Mackie, Brueggemann et al. 2008, Joshi, Sedivy et al. 2009, 
Zhong, Harhun et al. 2010, Mani, Brueggemann et al. 2011, Chadha, Zunke et al. 
2012, Khanamiri, Soltysinska et al. 2013, Zavaritskaya, Zhuravleva et al. 2013, 
Jepps, Carr et al. 2015, Morales-Cano, Moreno et al. 2015), pigs (Hedegaard, 
Nielsen et al. 2014), and humans (Ng, Davis et al. 2011), with many accompanying 
functional studies that emphasize the importance of Kv7 channels in the regulation 
vascular tone in these different vessels. Studies cited above emphasize that the 
regulation of vascular tone occurs due to the role of Kv7 channels in regulating the 
membrane potential of vascular smooth muscle cells; inhibition of Kv7 channels 
depolarizes vascular smooth muscle cell membranes and initiates contraction of 
vascular smooth muscle (Mackie, Brueggemann et al. 2008).  
Kv7 channels in airway smooth muscle. Kv7 channels were recently 
found to be expressed in airway smooth muscle. Guinea pig ASMCs express 
primarily Kv7.2, Kv7.4 and Kv7.5, (Brueggemann, Kakad et al. 2012), whereas 





expression of Kv7.2 and Kv7.3 (Brueggemann, Kakad et al. 2012, Evseev, 
Semenov et al. 2013, Brueggemann, Haick et al. 2014). The importance of Kv7 
channels as determinants of airway smooth muscle excitability has been 
emphasized by the electrophysiological and functional studies that have been 
completed in these tissues. Carbachol, methacholine, and histamine, Gq-coupled 
receptor agonists, inhibited Kv7 currents in freshly isolated airway myocytes from 
mouse, rat and guinea pig, respectively (Brueggemann, Kakad et al. 2012, Evseev, 
Semenov et al. 2013, Brueggemann, Haick et al. 2014). Activation of Kv7 channels 
was found to reverse airway constriction in rat (Brueggemann, Haick et al. 2014) 
and human precision cut lung slices (Brueggemann, Kakad et al. 2012), as well as 
contraction of mouse and rat tracheal rings (Evseev, Semenov et al. 2013). 
Evidence also suggests that nebulized retigabine may act as a bronchodilator in 
vivo. Evseev and colleagues found that retigabine attenuated the methacholine-
induced increase in enhanced pause (an indirect measurement of airway 
resistance (Lomask 2006, Frazer, Reynolds et al. 2011)), in mice (Evseev, 
Semenov et al. 2013). 
Targeting Kv7 channels in smooth muscle as a therapeutic strategy. 
The effects of modulating Kv7 channel activity in the smooth muscle beds listed 
above suggest that Kv7 channels may be novel therapeutic targets for a variety of 
conditions. Fortunately there are some Kv7 channel activators that are currently in 
clinical use for other applications. Flupirtine, while only clinically available as an 





the United States for the treatment of fibromyalgia. Retigabine has been clinically 
available in the United States as an adjuvant treatment for epilepsy in adults since 
mid-2011 (Harris and Murphy 2011) and although celecoxib’s current clinical use 
is limited to anti-inflammatory pain relief (McCormack 2011), it has been shown to 
enhance Kv7 currents in vascular and airway smooth muscle cells (Brueggemann, 
Mackie et al. 2009, Mani, Brueggemann et al. 2011, Brueggemann, Kakad et al. 
2012). Repurposing these drugs for the treatment of smooth muscle disorders is 
an attractive prospect and may be applicable for a number of diseases. 
Targeting Kv7 channels in the gastrointestinal tract may be a novel 
approach to treat functional dyspepsia or irritable bowel syndrome, both conditions 
associated with gastrointestinal mobility (Leake 2013, Soares 2014). Relaxing the 
smooth muscle found in the bladder with Kv7 channel activators may help to 
relieve symptoms associated with overactive bladder. Interestingly, and in support 
of this theory, urinary retention is one side effect associated with taking retigabine 
for the treatment of epilepsy (Brickel, Gandhi et al. 2012). Lastly, suppressing 
myometrial contraction is one therapeutic approach currently used to delay 
preterm labor. (Haas, Caldwell et al. 2012). Activation of the Kv7 channels in 
human myometrial smooth muscle at full term attenuated spontaneous myometrial 
contractions (McCallum, Pierce et al. 2011), suggesting that Kv7 channel 
activators may also represent a novel therapeutic approach to treat preterm labor. 
The ability of Kv7 channel activators to relax vascular smooth muscle and Kv7 





channels located in the vasculature a rapidly expanding area of interest (Mackie 
and Byron 2008, Jepps, Olesen et al. 2013, Stott, Jepps et al. 2014). These 
channels may be considered novel targets for the treatment of a variety of vascular 
disorders, including hypertension, pulmonary arterial hypertension, preeclampsia, 
cerebral vasospasm and subarachnoid hemorrhage, coronary artery disease, and 
hypotension (Haick and Byron 2016).  
As detailed previously, asthma is a disease that is partially characterized by 
reversible airway obstruction associated with exaggerated ASMC contraction and 
airway narrowing in response to bronchoconstrictor stimuli. Although there are a 
variety of treatments available, a surprisingly large portion of the asthmatic 
population has poor control over their disease (Peters, Jones et al. 2007, 
Chapman, Boulet et al. 2008). Despite the extensive efforts of researchers to 
elucidate the role of airway smooth muscle in the pathophysiology of asthma and 
identify new targets to treat the disease, no new pharmacological agents directed 
towards targets in ASMCs have become available in recent years. Those that have 
are often associated with unwanted side effects or poor selectivity for their targets 
(Janssen 2009, Siddiqui, Redhu et al. 2013, Dowell, Lavoie et al. 2014). Kv7 
channels are expressed in ASMCs across multiple species, their currents are 
inhibited by bronchoconstrictor agonists, and activation of Kv7 channels relaxes 
airways (Brueggemann, Kakad et al. 2012, Evseev, Semenov et al. 2013, 
Brueggemann, Haick et al. 2014). The specific mechanism(s) responsible for 





the potential of Kv7 channel activators to act as a novel treatment option for asthma 











HYPOTHESIS AND AIMS 
 
Main hypothesis: This project aims to test the hypothesis that Kv7 K+ channels in 
airway smooth muscle are regulated by the bronchoconstrictor agonist histamine 
in a PKC-dependent manner and that targeting these channels with clinically 
available Kv7 channel activators represents a novel strategy for bronchodilatory 
asthma therapy. 
 
Specific Aim 1: To elucidate the mechanism by which the bronchoconstrictor 
agonist histamine regulates Kv7 channels in airway smooth muscle. 
 Previous studies have revealed that Kv7 currents in guinea pig ASMCs are 
inhibited upon treatment with the Gq–coupled receptor bronchoconstrictor agonists 
histamine and methacholine (Brueggemann, Kakad et al. 2012). Silencing Kv7.5 
expression in freshly isolated rat ASMCs abolished detectable Kv7 currents, 
suggesting the functional importance of this particular subtype in mediating the 
Kv7 currents in airway smooth muscle (data not shown). Treatment of freshly 
isolated human trachealis smooth muscle with histamine or the PKC activator, 
phorbol 12-myristate 13-acetate (PMA), resulted in the increased presence of 
endogenous Kv7.5 channels in immunoprecipitates isolated using an antibody that 
recognizes phosphorylated serine residues that fall within the PKC consensus 





significance of this particular channel subtype. In vascular smooth muscle cells, 
Gq-coupled receptor stimulation results in PKC-dependent phosphorylation of 
Kv7.5 channels and inhibition of Kv7.5 currents (Brueggemann, Moran et al. 2007, 
Mackie, Brueggemann et al. 2008, Brueggemann, Mackie et al. 2014). We 
hypothesize that the Gq-coupled receptor agonist histamine phosphorylates Kv7.5 
channels and inhibits Kv7.5 currents in a PKC-dependent manner in airway 
smooth muscle as well.  
 ASMCs were isolated from human trachealis smooth muscle and cultured 
at low passages (HTSMCs). Wild type (WT) or mutant FLAG-tagged human Kv7.5 
(hKv7.5) channels were overexpressed using an adenoviral vector. 
Immunoprecipitation and western blotting approaches were used to examine the 
phosphorylation status of WT and mutant hKv7.5 channels and whole cell 
perforated patch clamp electrophysiology was used to measure WT and mutant 
hKv7.5 currents in response to treatment with histamine or direct activation of PKC 
with PMA.   
 
Specific Aim 2: To determine the efficacy of Kv7 channel activators in attenuating 
agonist-induced bronchoconstriction and explore their therapeutic potential for the 
treatment of asthma. 
In earlier studies, the Kv7 channel activator flupirtine attenuated histamine-
induced constriction of human airways and the Kv7 channel inhibitor XE991 





cut lung slices (PCLS) prepared from Sprague-Dawley rats and discarded human 
donor tissue were used to test the ability of the Kv7 channel activator retigabine to 
attenuate agonist-induced airway constriction. PCLS prepared from tissue of a 
guinea pig ovalbumin (OVA)-sensitization model of allergic asthma was used to 
compare the ability of retigabine to reverse bronchoconstriction in normal and 
asthmatic tissues. The ability of retigabine to alleviate the symptoms observed in 
sensitized animals upon exposure to OVA was tested in vivo, as was the ability of 
























MATERIALS AND METHODS 
Cell Culture. 
 HTSMCs were isolated as described previously (Janssen and Sims 1992, 
Brueggemann, Kakad et al. 2012) from de-identified donor tissues 
(approved/exempted by the Loyola University Chicago Institutional Review Board 
for the Protection of Human Subjects). Briefly, trachealis muscles were dissected 
in ice-cold dissecting solution, containing (in mM): 145 NaCl, 4.7 KCl, 1.2 
NaH2PO4, 1.2 MgSO4, 2 CaCl2_2H2O, 2 pyruvic acid, 0.02 EDTA dihydrate, 3 
MOPS, 5 D-glucose, and 1% fatty acid-free BSA (pH adjusted to 7.4 with NaOH 
on ice), cut into approximately 2 mm diameter strips, and immediately transferred 
to ice-cold physiological saline solution (PSS), containing (in mM): 140 NaCl, 5.36 
KCl, 0.34 Na2HPO4, 0.44 KH2PO4, 1.2 MgCl2, 0.05 CaCl2, 10 HEPES, and 10 D-
glucose (pH adjusted to 7.2 with NaOH on ice, 298 mOsm/l). Strips were then 
transferred into 37°C PSS (pH adjusted to 7.2 with NaOH at 37°C) supplemented 
with BSA (1 mg/ml; fraction V, Roche Diagnostics USA), collagenase Type VIII 
(950 units/ml; Sigma-Aldrich), papain (38 units/ml; Worthington), and DL-
dithiothreitol (1 mM; Sigma-Aldrich) for 45 min. Following enzymatic digestion, the 
tissue strips were washed three to five times with ice-cold PSS and gently triturated 
to release individual myocytes. Myocytes were cultured at low passages (2-9) in 





serum (Atlanta Biologicals), antibiotics and antimycotics (Sigma Aldrich) at 37°C 
under 5% CO2. 
Adenoviral infection. For overexpression of WT or mutant (S441A or 
T505A) human Kv7.5 (hKv7.5) channels, HTSMCs were infected at confluence 
with an adenoviral expression vector (Adv-hKCNQ5-FLAG-WT, Adv-hKCNQ5-
FLAG-S441A, or Adv-hKCNQ5-FLAG-T505A) at a multiplicity of infection (MOI) of 
100 for a minimum of 6 days prior to experimentation. Expression was confirmed 
by detection of green fluorescent protein (GFP) fluorescence (GFP is co-
expressed via the same hKCNQ5-FLAG adenoviral vector) and by western blot 
analysis. 
Retroviral infection. For knockdown of PKCα expression, a retroviral 
vector driving expression of a PKCα short hairpin RNA (shRNA) was employed 
essentially as described previously (Denning, Wang et al. 2002). HTSMCs were 
plated in 6 well plates at 105 cells per well. Approximately 24 hr later, shControl or 
shPKCα retroviral supernatants supplemented with 4 µg/ml hexadimethrine 
bromide (Sigma-Aldrich) were added to the appropriate wells and plates were spun 
at 300 x g for 1 hr at 32°C. Viral supernatants were immediately replaced with fresh 
culture medium. For some experiments this process was repeated after 
approximately 6 hr to assure adequate infection. The following day, cells were 
washed twice with phosphate-buffered saline and then incubated with media 





purposes. Effective knockdown of shPKCα expression was confirmed by western 
blot analysis. 
Constructs used for infections. An adenoviral vector to express human 
KCNQ5-WT (Adv-hKCNQ5-FLAG-WT, with a FLAG epitope on the amino 
terminus), human KCNQ5-S441A (Adv-hKCNQ5-FLAG-S441A, with a FLAG 
epitope on the amino terminus), or human KCNQ5-T505A (Adv-hKCNQ5-FLAG-
T505A, with a FLAG epitope on the amino terminus) were created previously using 
the AdEasy Adenoviral Vector System (Stratagene). Retroviral vectors to express 
shRNA targeting human PKCα (shPKCα, AGGCUGAGGUUGCUGAUGA) or 
shRNA targeting a sequence not found in the human genome (shControl, 
GCGCGCTTTGTAGGATTCG) were created previously using the 




Whole-cell membrane currents in single HTSMCs overexpressing hKv7.5 
channels (infected with Adv-hKCNQ5-FLAG WT, S441A or T505A for a minimum 
of 6 days) were measured using perforated patch configurations under voltage-
clamp conditions. Cells were trypsinized and allowed to attach to glass coverslips 
for 15-20 min at 37°C. Experiments were performed at room temperature while 
being continuously perfused with an external bath solution containing (in mM): 5 





Standard internal (pipette) solution contained (in mM): 110 potassium gluconate, 
30 KCl, 5 HEPES, 1 K2EGTA (pH 7.2, 298 mOsm) and was supplemented with 
120 μg/ml Amphotericin B immediately prior to experimentation for patch 
perforation. 
Voltage-clamp command voltages were generated using an Axopatch 200B 
amplifier (Molecular Devices) under control of pCLAMP 10 (Molecular Devices). 
Series resistances after amphotericin perforation were 20-35 MΩ and were 
compensated by 40%. Whole-cell currents were digitized at 2 kHz and filtered at 1 
kHz.  
Exogenous hKv7.5 currents were recorded using a 5 sec voltage step 
protocol from a -74mV holding potential to test voltages ranging from -124 mV to -
4 mV, followed by a 1 sec step to -120 mV. The currents recorded during the last 
1 sec of recording time for each voltage step were averaged and normalized by 
cell capacitance to obtain end-pulse steady-state hKv7.5 currents. The time course 
of drug application was recorded with repetitive 5 sec steps from -74 to -20 mV 
every 5 sec. 
 
Immunoprecipitation and Western Blot Analysis. 
 HTSMCs were infected with Adv-hKCNQ5-FLAG-WT or Adv-hKCNQ5-
FLAG-S441A at 100 MOI for 6 days and serum deprived overnight prior to 
experimentation. On the day of the experiment, HTSMCs were incubated for 3 hr 





KCl, 135 NaCl, 11.6 HEPES, 1.5 CaCl2, 1.2 MgCl2, 11.5 glucose (pH 7.3) prior to 
treatment. Immediately following treatment, cells were lysed with ice-cold lysis 
buffer containing 100 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 
30 mM sodium pyrophosphate, 5 mM β-glycerophosphate, 20 mM HEPES (pH 
7.4) and supplemented with 10 µg/ml leupeptin (Bachem), 0.5 mM 
phenylmethanesulfonyl fluoride (Sigma-Aldrich) or Pefabloc (Acros Organics), 10 
µg/ml aprotinin (Sigma-Aldrich) and 500 µM Na3VO4. Equal protein concentrations 
of cell lysates (350-500 µg) were incubated overnight at 4C with 4 µg of anti-FLAG 
antibody (Sigma-Aldrich, F7425). 20 µl of Dynabeads® Protein G (Invitrogen, Life 
Technologies) were added to antibody-containing lysates and incubated for 2 hr at 
4C. The beads were washed and immune complexes were eluted with 1X 
Laemmli sample buffer (5% SDS, 10% glycerol, 50 mM Tris, pH 6.8, 0.01% 
bromophenol blue, 10% β-mercaptoethanol, 100 mM dithiothreitol), heated for 5 
min at 97C and separated by SDS-PAGE on 10% acrylamide gels. Proteins were 
transferred to polyvinylidene fluoride membranes, blocked in 5% nonfat milk, and 
probed with anti-phosphoserine PKC substrate antibody (rabbit polyclonal 1:1000, 
Cell Signaling Technology, 2261) overnight at 4°C. Membranes were washed and 
then probed with anti-rabbit IgG HRP-conjugated secondary antibody (1:10,000, 
Thermo Scientific, 31460) for 1 hr at room temperature. For immunoprecipitation 
(IP) loading controls, 25 µg of protein from lysates for each IP sample were run on 





sodium azide and then re-probed with anti-FLAG M2 peroxidase conjugate (mouse 
monoclonal 1:10,000, Sigma-Aldrich, A8592) for 1 hr at room temperature.  
To confirm PKCα knockdown, 25 µg of protein from lysates for each 
experiment were run on separate 10% acrylamide gels, probed with anti-PKCα 
(mouse monoclonal 1:1000, BD Biosciences, 610108) overnight at 4C, washed, 
and then probed with anti-mouse IgG HRP-conjugated secondary antibody 
(1:10,000, Thermo Scientific, 31430) for 1 hr at room temperature. For loading 
controls, membranes were incubated with anti-GAPDH (mouse monoclonal 
1:1000, Novus Biologicals, NB300-221) for 1 hr at room temperature, washed, and 
then probed with anti-mouse IgG HRP-conjugated secondary antibody for 1 hr at 
room temperature.  
Western blot results were visualized using enhanced chemiluminescence 
(Optiblot ECL Detect Kit, abcam or Amersham ECL Prime Western Blotting 
Detection Reagent, GE Healthcare Life Sciences).  ImageJ software was used for 
densitometry analysis.  
 
[Ca2+]cyt Measurements with Fura-2. 
 Confluent monolayers of cultured HTSMCs in six-well plates were serum 
deprived overnight prior to experimentation. On the day of experiment, cells were 
washed twice with mKreb’s buffer at room temperature and background 
fluorescence was recorded using a Biotek Synergy HT plate reader (340 and 380 





Winooski, VT). Cells were then incubated in mKreb’s plus 1μM fura-2 
acetoxymethyl ester (Invitrogen), 0.1% bovine serum albumin, and 0.02% Pluronic 
F127 detergent for 90 min at room temperature in the dark. After this fura-2 loading 
period, cells were washed twice with mKreb’s and incubated for an additional 60 
min in mKreb’s at room temperature in the dark. Changes in [Ca2+]cyt in response 
to treatments were estimated based on fura-2 fluorescence measured at 510 nm 
with alternating excitation at 340 and 380 nm wavelengths. Background values 
were subtracted from each wavelength prior to calculating the 340/380 
fluorescence ratio. Values were normalized to the average fluorescence ratio 
recorded during the 2-min period prior to treatment. Sustained elevation of [Ca2+]cyt 
in response to treatment was evaluated based on the average fluorescence ratio 
recorded during the 5-min period beginning 10 min after initiation of treatment. 
Each “n” is the average of 3-6 wells. 
 
Immunofluorescence. 
 Freshly isolated HTSMCs and HTSMC at passages 2, 4, 6, and 8 were 
plated on 12 mm coverslips 1 day prior to fixing. The cells were fixed with 4% 
paraformaldehyde in phosphate-buffered saline and permeabilized with 0.5% 
Triton X 100 in phosphate-buffered saline. Coverslips were incubated in Image-iT 
signal enhancer (Thermo Fischer Scientific) prior to blocking. A coverslip from 
each passage was incubated with polyclonal goat anti-SM22α (abcam, ab10135) 





4°C overnight. Alexa Fluor® 488 rabbit anti-goat IgG or Alexa Fluor® 594 goat anti-
rabbit at 1:400 dilution were used as secondary antibodies. Each coverslip was 
treated with SlowFade Antifade Equilibration Buffer (Molecular Probes, Eugene, 
OR) and ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) 
prior to mounting on a glass slide. Cell images were acquired with an Olympus 
1X71 inverted epifluorescence microscope, a Hamamatsu Orca 12-bit digital 
camera, and Simple PCI software. SM22α images were captured with a 0.1 second 
exposure using a 505 nm LP dichroic filter (480/40 nm excitation filter, 535/50 nm 
emission). Kv7.5 images were captured with a 0.5 second exposure using a 564 
nm LP dichroic filter (535/50 nm excitation filter, 620/60 nm emission). DAPI 
images were captured with a 0.2 second exposure using a 400 nm LP dichroic 
filter (340 & 380 nm filters in Sutter DG-4). Coverslips incubated without primary 




HTSMCs were grown to confluence on 150 mm dishes and infected at 100 
MOI with Adv-hKCNQ5-FLAG-WT or Adv-hKCNQ5-FLAG-S441A or at 500 MOI 
with Adv-hKCNQ5-FLAG-T505A for 6 days and serum deprived overnight prior to 
experimentation. On the day of the experiment, HTSMCs were incubated for 3 hr 
at room temperature in mKreb’s prior to treatment. Immediately following 





of cell lysates (1.1 mg) were incubated overnight at 4C with 4 µg of anti-FLAG 
antibody. 20 µl of Dynabeads® Protein G were added to antibody-containing 
lysates and incubated for 2 hr at 4C. The beads were washed and immune 
complexes were eluted with 1X Laemmli sample buffer, heated for 5 min at 97C, 
and stored at -20°C until further use by Dr. Kolla Kirstjansdottir at Midwestern 
University, Downers Grove, IL.  
Enzymatic digestion. Samples were separated by SDS-PAGE on 10% 
acrylamide gels. Gel was stained with Coomassie Brilliant Blue to identify the 
bands for analysis. These bands were excised using a razor blade and cut into 
approximately 1 mm3 pieces. Each piece was washed in water and destained 
using 100 mM ammonium bicarbonate (NH4HCO3, pH 7.5) in 50% acetronitrile. 
The reduction step was performed by the addition of 100 µl 50 mM NH4HCO3 (pH 
7.5) and 10 µl 10 mM Tris(2-carboxyethyl)phosphine HCl for 30 min at 37°C. 
Proteins were alkylated by adding 100 µl 50 mM iodoacetamide for 30 min at 20°C 
in the dark. The gel sections were then washed in water, then acetonitrile, and 
dried in a SpeedVac. 
 Samples were digested with either endoproteinase Glu-C (EndoQ) or 
endoproteinase Lys-C (EndoK). EndoQ digestion was carried out with 160 ng 
Mass Spectrometry Grade Glu-C enzyme (Thermo #90054) in 50 mM NH4HCO3 
(pH 7.5) overnight at 37°C. EndoK digestion was carried out with 160 ng Mass 





(pH 7.5) overnight at 37°C. Peptides were extracted with 5% formic acid, vacuum 
dried, and sent to Don Wolfgeher at the University of Chicago (Chicago, IL). 
High Performance Liquid Chromatography for mass spectrometry. 
Samples were then re-suspended Burdick & Jackson HPLC-grade water 
containing 0.2% formic acid (Fluka), 0.1% TFA (Pierce), and 0.002% Zwittergent 
3–16 (Calbiochem), a sulfobetaine detergent (MH+ at 392, and in-source dimer 
[2 M + H+] at 783, and some minor impurities of Zwittergent 3–12 seen as MH+ at 
336; peaks that will be at the end of the chromatograms). Peptide samples were 
loaded to a 0.25 μl C8 OptiPak trapping cartridge custom-packed with Michrom 
Magic (Optimize Technologies) C8, washed, then switched in-line with a 20 cm by 
75 μm C18 packed spray tip nano column packed with Michrom Magic C18AQ, for 
a 2-step gradient. Mobile phase A was water/acetonitrile/formic acid (98/2/0.2) and 
mobile phase B was acetonitrile/isopropanol/water/formic acid (80/10/10/0.2). A 
flow rate of 350 nl/min was used during a 90 min, 2-step LC gradient: 60 min from 
5% B to 50% B, 10 min 50%–95% B, 10 min hold at 95% B, and then back to 
starting conditions and re-equilibrated. 
Liquid Chromatography-MS/MS analysis. Samples were analyzed via 
electrospray tandem mass spectrometry (LC–MS/MS) on a Thermo Q-Exactive 
Orbitrap mass spectrometer. A 70,000 RP survey scan in profile mode, m/z 360–
2000 Da, with lockmasses was used, followed by 20 MSMS HCD fragmentation 





ions were excluded, and ions selected for MS/MS were placed on an exclusion list 
for 60 sec. 
 Tandem mass spectra were extracted, charge state deconvoluted and 
deisotoped by Proteowizard MSconvert version 3.0.9134. Mascot (Matrix Science, 
London, UK; version 2.3.02) and X! Tandem (The GPM, thegpm.org; version 
CYCLONE (2010.12.01.1)) were set up to search the 
160107_SPROT_Human_Iso_UP000005640 database (1-07-2016, 92013 
entries) assuming the digestion enzymes Lys-C of Glu-C (V8). Fragment search 
specifications include an ion mass tolerance of 0.40 Da and a parent ion tolerance 
of 10.0 PPM. Fixed modification settings included Carbamidomethyl of cysteine. 
Variable modification settings included de-amidated of asparagine and glutamine, 
oxidation of methionine, formyl of the n-terminus and phospho of serine, threonine 
and tyrosine in Mascot and Glu->pyro-Glu of the n-terminus, ammonia-loss of the 
n-terminus, gln->pyro-Glu of the n-terminus, de-amidated of asparagine and 
glutamine, oxidation of methionine, formyl of the n-terminus and phospho of serine, 
threonine and tyrosine in X! Tandem. 
Criteria for protein identification. Validation of MS/MS based peptide and 
protein identifications was made using Scaffold (version Scaffold_4.7.5, Proteome 
Software Inc., Portland, OR). Peptide identifications were accepted if they could 
be established at greater than 87.0% probability to achieve a false discovery rate 
less than 1.0%. The Mascot peptide probabilities were assigned by the Scaffold 





assigned by the Peptide Prophet algorithm (Keller, Nesvizhskii et al. 2002) with 
Scaffold delta-mass correction. The criteria for acceptable protein identifications 
included containing at least 2 identified peptides and a greater than 6.0% 
probability to achieve a false discovery rate less than 1.0%, with the probabilities 
being assigned by the Protein Prophet algorithm (Nesvizhskii, Keller et al. 2003). 
Proteins that could not be differentiated by MS/MS analysis due to similar peptides 
were grouped to satisfy the principles of parsimony and proteins that shared 
significant peptide evidence were grouped into clusters. Proteins were annotated 
with gene ontology terms from NCBI (downloaded Mar 10, 2016 (Ashburner, Ball 
et al. 2000)). 
Post-translational modification site localization. Post-translational 
modification sites were annotated using Scaffold Post-Translational Modification 
(version Scaffold_4.4.6, Proteome Software, Portland, Oregon, USA). The site 
localization algorithm developed by Beausoleil et al. (Beausoleil, Villen et al. 2006) 
was used to re-analyze MS/MS spectra identified as modified peptides and 
develop a score that is calculated to assess the level of confidence in each PTM 
localization. Localization probabilities for all peptides containing each identified 
post-translational modification site are combined to obtain the best estimated 








Animal Welfare and Housing. 
 Male Sprague-Dawley rats were purchased from Harlan Laboratories 
(Indianapolis, IN). Animals were housed in pairs in standard cages and fed with 
standard chow in a 12 hr dark-light cycle. All procedures were approved by the 
Institutional Animal Care and Use Committee, Loyola University Medical Center, 
Maywood, IL and were executed in accordance with the National Academy of 
Sciences Guide for the Care and Use of Laboratory Animals. 
 Male Hartley guinea pigs were purchased from Harlan Laboratories or 
Charles River Laboratories (Skokie, IL). Animals were housed in pairs in standard 
cages and fed with standard chow in a 12 hr dark-light cycle. All procedures were 
approved by the Institutional Animal Care and Use Committee (Loyola University 
Medical Center, Maywood, IL or Edward Hines, Jr. Veterans Affairs Hospital, 
Hines, IL) and were executed in accordance with the National Academy of 
Science’s Guide for the Care and Use of Laboratory Animals. 
 
Guinea Pig Sensitization Model. 
 Male Hartley guinea pigs, 250-350g, were given 3 intraperitoneal injections 
of OVA (100 µg OVA and 100 mg aluminum hydroxide in 1 ml saline) or saline 
alone (control) on days 1, 3 and 5. Following a 2 week sensitization period, on day 
19 the animals were exposed to a fine mist of OVA (5 mg/ml) in a cylindrical 
plexiglass chamber for 30 min. Control guinea pigs did not display any symptoms. 





labored breathing, and gasping within 5-10 min, followed by more severe 
symptoms, including coughing, cyanosis, and convulsions, at approximately 15 
min into the challenge prompting their removal from the chamber and cessation of 
the challenge. This procedure was repeated on days 20 and 21. Tissues were 
collected post-euthanasia for study on day 22. 
Tissue collection. Guinea pigs were euthanized by intraperitoneal injection 
of sodium pentobarbital or Euthasol®. The trachea was cut and cannulated with a 
3 mm outer-diameter polypropylene-barbed tubing connector connected to 3-way 
stopcock and two 10 mL syringes. The lungs and heart were excised and placed 
into a modified Hank’s balanced salt solution (mHBSS) containing (in mM): NaCl 
137.9, KCl 5.33, CaCl2 1.26, MgCl2 0.49, MgSO4 0.41, HEPES 20, KH2PO4 0.44, 
Na2HPO4 0.34, D-glucose 5 (pH 7.4 at 37°C, 298–300 mOsm) that had been 
preheated to 37°C.  
Precision cut lung slices. Approximately 5 mL of air was withdrawn from 
the lungs to deflate them followed by inflation of the lungs with 20-25 mL of 2% 
low-melting temperature agarose in mHBSS 37°C supplemented with 1 μM 
isoproterenol. 5 mL of air was injected back into the lungs following inflation with 
agarose and tissue was cooled in mHBSS 4°C (pH 7.4 at 4°C, 298-300 mOsm) for 
30 min to allow for agarose solidification. Lobes were then separated, trimmed 
perpendicular to the bronchus, and sliced 500 μm thick using a Leica VT 1200S 
vibratome (Leica Microsystems, Buffalo Grove, IL). Lung slices were incubated in 





insulin-transferrin-selenium (Sigma-Aldrich), antibiotics and antimycotics (Sigma-
Aldrich), and 1 μM isoproterenol for 4-6 hours and then changed to medium with 
no isoproterenol overnight. The slices were kept at 37°C in 5% CO2 and used for 
up to 4 days after preparation.  
If guinea pig lung slices are taken out of media immediately prior to 
experimentation, airways often go through a slow contraction and relaxation cycle 
that lasts approximately 4-6 hours in which the airways will be nonresponsive to 
bronchoconstrictor agonist treatment. Therefore, slices that contained round, open 
airways with beating cilia, and an intact airway wall and surrounding parenchyma 
attachments were selected and incubated overnight at room temperature in control 
medium containing (in mM) 140 NaCl, 5.36 KCl, 1.2 MgCl2, 2 CaCl2, 10 HEPES, 
10 D-glucose (pH 7.3, 298 mOsm/l) so as to avoid the contraction-relaxation cycle 
and to promote a more stable airway diameter for experimentation.   
 To measure airway area, a lung slice was mounted in a perfusion chamber 
located on the stage of an Olympus IX-71 inverted microscope and a single airway 
was visualized using a 5X or 10X objective. All experiments were completed at 
room temperature. The lung slice was perfused with control medium (~1 drop/sec) 
for 20 minutes, or until a stable baseline area was achieved for 20 minutes, prior 
to perfusion of control medium containing drug. Images were captured every 5 sec 
with a Hamamatsu Orca 12-bit digital camera and luminal airway area was 






Human Precision Cut Lung Slices. 
 Human lung tissue not suitable for transplantation was obtained from Dr. 
Jeffrey Schwartz of the Department of Thoracic and Cardiovascular Surgery at 
Loyola University Chicago or from Dr. Julian Solway at the University of Chicago. 
Tissue was infused with injections of 2% low-melting temperature agarose in 
mHBSS at 37°C and cooled in mHBSS 4°C to allow for solidification of agarose. 
Once solidified, tissue was sliced 0.5-1 mm thick perpendicular to airways using a 
Leica VT 1200S vibratome. Lung slices were incubated in serum-free tissue culture 
F-12/DMEM medium supplemented with insulin-transferrin-selenium (Sigma-
Aldrich) and antibiotics and antimycotics (Sigma-Aldrich). The slices were kept at 
37°C in 5% CO2 and used for up to 4 days after preparation. 
 To measure airway area, a lung slice was mounted in a perfusion chamber 
located on the stage of an Olympus IX-71 inverted microscope and a single airway 
was visualized using a 5X or 10X objective. All experiments were completed at 
room temperature. The lung slice was perfused with control medium (~1 drop/sec) 
for 20 minutes, or until a stable baseline area was achieved for 20 minutes, prior 
to perfusion of control medium containing drug. Images were captured every 5 sec 
with a Hamamatsu Orca 12-bit digital camera and luminal airway area was 








Guinea Pig flexiVent Optimization Experiments. 
 Naïve male Hartley guinea pigs (250-550 g) were weighed and anesthetized 
with intraperitoneal injection of Inactin® (thiobutabarbital, 300-400 mg/kg, given 
100 mg/kg initially followed by 50 mg/kg increments every 15 minutes until the 
animal is fully anesthetized). The trachea was cannulated the animal was 
ventilated using a computer-controlled small animal ventilator (flexiVent, SCIREQ, 
Montréal, QC, Canada) at a rate of 60 breaths/minute and a tidal volume of 5 ml/kg. 
Respiratory resistance was measured using the flexiVent “snapshot” maneuver (1 
second duration, 1 Hz frequency) and Newtonian resistance, tissue dampening, 
and tissue elastance were measured using the flexiVent “quick prime-6” maneuver 
(6 second duration, 1-20.5 Hz frequency) using flexiWare software (flexiVent, 
SCIREQ, Montréal, QC, Canada). Once a stable baseline resistance value was 
obtained, the animals were given doses of histamine or methacholine using either 
an intravenous (i.v.) catheter or an in-line computer-controlled Aeroneb Lab 
nebulizer at approximately 5-minute intervals. For i.v. administration, 100 µl of 
each concentration in saline was injected followed by a 50 µl heparinized saline 
flush (50 U/ml). For nebulized administration, 200 µl of each concentration in water 
was pipetted onto the nebulizer. After each administration of bronchoconstrictor, 
the peak resistance value was recorded using a series of “snapshot” and “quick 
prime-6” maneuvers for 5 minutes prior to the next administration. At the end of 
each experiment, animals were euthanized via intraperitoneal injection of 






Data are expressed as mean ± standard error of the mean (S.E.). SigmaStat 
(Systat Software, Inc.) was used for all statistical analyses. Independent t-test or 
the t-test followed by the Mann-Whitney Rank Sum test was used for comparisons 
between two independent groups. Paired Student’s t-test was used for 
comparisons of parameters measured before and after treatments. Comparisons 
between more than two independent treatment groups were evaluated by analysis 
of variance (ANOVA) followed by the Holm-Sidak post hoc test. Comparisons 
among multiple treatments of the same subject (cell or airway) were evaluated by 
repeated measures ANOVA followed by the Holm-Sidak post hoc test. Differences 














Cultured HTSMCs Retain SM22α Expression. 
 Culturing ASMCs to study the regulation of airway smooth muscle 
responses at the cellular level, including cell signaling and regulation of protein 
expression, is a method that has been in place for decades (Hall and Kotlikoff 
1995). We considered it necessary to confirm that the smooth muscle phenotypes 
persisted upon the culturing of HTSMCs by using immunofluorescence to confirm 
the expression of SM22α, a protein that is largely specific for smooth muscle (Lees-
Miller, Heeley et al. 1987), in freshly isolated HTSMCs cultured to passage 8 
(Figure 2). 
 
Histamine Increases [Ca2+]cyt in Cultured HTSMCs. 
   As described in detail in chapter 2, bronchoconstrictor agonists induce a 
biphasic increase in [Ca2+]cyt that is necessary for ASMC contraction. To confirm 
that the cultured HTSMCs retain this Ca2+ response to the bronchoconstrictor 
histamine, fura-2 fluorescence techniques were used to monitor changes in 
[Ca2+]cyt. Treatment of cultured HTMSCs with 1 µM histamine resulted in a 1.445-
fold increase in sustained [Ca2+]cyt over initial control levels (Figure 3B). 
To examine the involvement of L-type VSCCs in the sustained increase in 







Figure 2. Cultured HTSMCs express SM22α through passage 8. The top row 
of panels are representative images of freshly isolated (far left) or cultured 
HTSMCs (passages 2, 4, 6, and 8) expression of SM22α. The second row of 
panels are the same field, but showing DAPI stained nuclei of the cells imaged in 
the top row. The third row of panels are representative images of the minus primary 
SM22α antibody control. The fourth row of panels are the same field, but showing 
DAPI stained nuclei of the cells shown in the third row.  
 
VSCC blocker verapamil (10 µM). The increase in sustained [Ca2+]cyt was 
significantly smaller (1.209-fold over initial control levels, Figure 3B) than observed 
with histamine treatment alone, confirming a role for L-type VSCC in Ca2+ influx 
following bronchoconstrictor agonist treatment.  
 It is also worth noting that the Kv7 channel blocker XE991 (10 µM) induced 








Figure 3. Histamine induces L-type VSCC-dependent increases in [Ca2+]cyt in 
cultured HTSMCs. (A) Averaged time courses of [Ca2+]cyt following treatment of 
cultured HTSMCs with histamine (1 µM, closed circles, n=15) or histamine plus 
verapamil (10 µM, open circles, n=14). (B) Summary of 5 experiments (triplicate 
wells). Data shows average [Ca2+]cyt for the final 10-15 minutes of treatment 
(“sustained” [Ca2+]cyt increases) with histamine (black bar) or histamine plus 
verapamil (white bar). (C) Summary of 3 experiments (triplicate wells). Data shows 
average [Ca2+]cyt for the final 10-15 minutes of treatment (“sustained” [Ca2+]cyt 
increases) with Kv7 channel blocker XE991 (10 µM, dark grey bar). NOTE: All 
values were normalized to the average F340/380 values recorded during the 2 
minutes prior to treatment. *, significant difference from indicated groups, p < 0.05, 
one way ANOVA followed by Holm-Sidak post hoc test multiple comparisons 
among all groups. #, significantly different from control, p < 0.05, paired t-test. 
 
Activation of PKC Suppresses hKv7.5 Currents in Cultured HTSMCs.  
 
HTSMCs were cultured at low passages and used as an expression system 
to study the regulation of WT or mutant hKv7.5 channels. Similar to previous 
observations our laboratory has made regarding endogenous Kv7 currents 
(Brueggemann, Kakad et al. 2012, Haick, Brueggemann et al. 2017), in cultured 
HTSMCs overexpressing WT hKv7.5 channels, the application of histamine (1 μM) 
significantly suppressed hKv7.5 currents (by 34.4 ± 6.2% at -20 mV, Figure 4C) 
approximately 1-2 minutes following the start of histamine treatment (Figure 4B).  





chlorpheniramine (30 μM) before being treated with histamine, no hKv7.5 current 
inhibition was observed (Figure 4D). The vehicle for chlorpheniramine did not have 
an effect on hKv7.5 currents (data not shown). Pretreatment with the PKC inhibitor 
Ro-31-8220 (3 μM) for 1 hour prior to histamine treatment significantly attenuated 
the amount of histamine-induced hKv7.5 suppression that was observed (9.66 ± 
3% at -20 mV, Figure 5) compared to treatment with histamine alone (by 34.4 ± 
6.2% at -20 mV, Figure 4C). The direct activation of PKC with PMA (1 nM, Figure 
6A), also induced significant suppression of hKv7.5 currents (by 75.5 ± 7.6% and 
10.2 ± 4.9%, respectively, at -20 mV). No current suppression was observed 
following treatment with PMA’s inactive analog, 4α-PMA (1 nM, Figure 6B). 
 
Activation of PKC Induces Phosphorylation of hKv7.5 Channels in Cultured 
HTSMCs. 
We next wanted to test the effects of PKC activation with either histamine 
or PMA on hKv7.5 channel phosphorylation. A FLAG antibody was used to 
immunoprecipitate FLAG-tagged hKv7.5 channels following no treatment, 
treatment with histamine (1 µM) for 10 minutes, or treatment with PMA (1 nM) for 
30 minutes. An antibody that recognizes phosphorylated serine residues that fall 
within a specific PKC consensus motif (anti-phosphoserine PKC substrate) was 
used to examine hKv7.5 channel phosphorylation. This antibody recognizes 
phosphorylated serine residues that fall within the conventional PKC consensus 







Figure 4. Histamine inhibits hKv7.5 currents in cultured HTSMCs. (A) 
Representative traces of hKv7.5 currents recorded with a voltage-step protocol 
(see materials and methods) in one cultured HTSMC, i, before and, ii, after 
treatment with 1 µM histamine (capacitance = 100 pF). (B) Averaged time course 
of histamine-induced hKv7.5 current inhibition at -20 mV in cultured HTSMCs 
(n=5). Normalized to average current 5 minutes prior to treatment with histamine. 
(C) Current-voltage (I-V) curves of steady state currents through hKv7.5 channels 
recorded in cultured HTSMCs before (filled circles) and after treatment with 
histamine (1 µM, open circles, n=6). (D) I-V curves of steady state currents through 
hKv7.5 channels recorded in cultured HTSMCs before (filled circles) treatment with 
chlorpheniramine (30 µM, open circles) and then histamine (1 µM) in the continued 
presence of chlorpheniramine (filled triangles, n = 4). *, significantly different from 
control, p < 0.05, paired t-test. 
 
acid (phenylalanine, isoleucine, leucine, valine, or tyrosine) is commonly found at 
the +1 position.  
Indirect activation of PKC with histamine and direct activation of PKC with 
PMA both resulted in a significant increase in hKv7.5 phosphorylation compared 







Figure 5. Histamine-induced inhibition of hKv7.5 currents in cultured 
HTSMCs is dependent on PKC. (A) I-V curves of stead state currents through 
hKv7.5 channels recorded in cultured HTSMCs pretreated with for 1 hour with Ro-
31-8220 (3 µM) before (filled circles) and after histamine (1 µM, open circles) 
treatment (n=5). (B) Summarized data shows average hKv7.5 current at -20 mV 
under control conditions (black bar), following treatment with histamine (1 µM, grey 
bar, n=6), or after 1 hour Ro-31-8220 (3 µM) pretreatment prior to histamine 
treatment (red bar, n=5). *, significantly different from control, p < 0.05, paired t-
test. ‡, significant difference from indicated groups, p < 0.05, one way ANOVA 
followed by Holm-Sidak post hoc test, with multiple comparisons among all groups. 
 
untreated control, respectively, Figure 7C). Pretreatment with the PKC inhibitor 
Ro-31-8220 (1 hour, 1, 3, and 10 μM) significantly attenuated histamine-induced 
phosphorylation of hKv7.5 (Figure 7D).  
In retrospect, a time course examining the phosphorylation status of hKv7.5 
following histamine treatment should have been completed in order to determine 
the optimal time point for experimentation. Before completing the additional 
experiments to examine the PKC isoform or the amino acid residues involved in 
histamine-induced phosphorylation of hKv7.5, we examined the level of hKv7.5 
phosphorylation following 30 seconds, and 1, 2, 5, 10, or 30 minutes of histamine, 





the first two minutes of treatment (3.36 ± 1.52 -fold, 2.54 ± 0.97 -fold, and 2.47 ± 
0.58 -fold greater than untreated control, at 30 seconds, 1 minute, and 2 minutes, 
respectively) and eventually declined to near control levels by 10 and 30 minutes 
(1.27 ± 0.19 –fold and 1.39 ± 0.39 –fold greater than untreated control, 
respectively, Figure 8). The initial increase in hKv7.5 channel phosphorylation 
corresponds with the time course observed for histamine-induced hKv7.5 current 
inhibition (Figure 4B). The 1 minute time point was selected for the remaining 
experiments. 
 
PKCα is Necessary for the Regulation of hKv7.5 Currents by Histamine, but 
not for Channel Phosphorylation.  
 PKCα is known to be activated following the activation of the H1 histamine 
receptor (Eto, Kitazawa et al. 2001, Megson, Walker et al. 2001, Rimessi, Rizzuto 
et al. 2007) and studies completed in A7r5 cells and rat mesenteric artery smooth 
muscle cells have suggested that the activation of PKCα is sufficient to suppress 
Kv7 currents in vascular smooth muscle (Brueggemann, Mackie et al. 2014). In 
order to determine if histamine-induced suppression of hKv7.5 currents in ASMCs 
is mediated by PKCα, we infected cultured HTSMCs with a retroviral vector that 
drives the expression of shRNA against PKCα (shPKCα), or control vector 







Figure 6. PMA, but not 4α-PMA, inhibits hKv7.5 currents in cultured HTSMCs. 
(A) I-V curves of steady state currents through hKv7.5 channels recorded in 
cultured HTSMCs before (filled circles) and after treatment with PMA (1 nM, open 
circles, n=4). (B) I-V curves of steady state currents through hKv7.5 channels 
recorded in cultured HTSMCs before (filled circles) and after treatment with 4α-
PMA (1 nM, open circles, n=3). *, significantly different from control, p < 0.05, 
paired t-test. 
 
studies described above. PKCα knockdown was confirmed by western blotting 
(Figure 10A). There was no histamine-induced suppression of hKv7.5 currents in 
cells that lacked PKCα (Figure 9A). Cells that lacked PKCα also had a significantly 
smaller histamine-induced increase in sustained [Ca2+]cyt compared to control cells 
(Figure 9D). Unexpectedly, knocking down PKCα did not prevent the significant 
increase in histamine-induced phosphorylation of hKv7.5 channels on serine 
residues located in the PKC consensus motif (1.48 ± 0.23 fold above untreated 
control, Figure 10).  
 
Threonine Residue 505 may be Necessary for the Regulation of hKv7.5 
Currents by Histamine. 
 Serine residue 541 in rat Kv7.2 is phosphorylated by PKC and required for 







Figure 7. PKC activation promotes hKv7.5 channel phosphorylation in 
HTSMCs. (A) Representative western blot of FLAG immunoprecipitates from 
cultured HTSMCs overexpressing FLAG-hKv7.5 channels that were left untreated, 
treated with histamine (1 µM, 10 minutes), or treated with PMA (1 nM, 30 minutes) 
probed with an anti-phosphoserine PKC substrate antibody (top). Whole cell 
lysates (50 µg) were run separately and probed with an anti-FLAG antibody to 
serve as a loading control (bottom). (B) Representative western blot of 
immunoprecipiates from cultured HTSMCs overexpressing FLAG-hKv7.5 
channels that were left untreated, treated with histamine (1 µM, 10 minutes), or 
pretreated with Ro-31-8220 (1, 3, or 10 µM, 1 hour) prior to histamine treatment 
probed with an anti-phosphoserine PKC substrate antibody (top). Whole cell 
lysates (50 µg) were run separately and probed with an anti-FLAG antibody to 
serve as a loading control (bottom). (C) Densitometry summarized from 11 
experiments depicted in A. (D) Densitometry summarized from 5 different 
experiments depicted in B. *, significantly different from control, p < 0.05, one-way 
ANOVA followed by Holm-Sidak post hoc test multiple comparisons versus control 
group. #, significantly different from histamine group, p < 0.05, one-way ANOVA 








Figure 8. Time course of histamine-induced phosphorylation of hKv7.5 
channels in cultured HTSMCs. Summarized densitometry results from 
immunoprecipitation experiments examining the phosphorylation of hKv7.5 
channels in HTSMCs following treatment with vehicle (mKreb’s buffer) or 1 µM 
histamine for 0.5, 1, 2, 5, 10 or 30 minutes. hKv7.5 channels were 
immunoprecipitated with an anti-FLAG antibody and western blots were probed 
with an anti-phosphoserine PKC substrate antibody. Whole cell lysates (25 µg) 
were run separately and western blots were probed using an anti-FLAG antibody 
to serve as a loading control. Anti-phosphoserine PKC substrate signals were 
normalized to anti-FLAG signals from whole cell lysates and vehicle and histamine 
treatments were then normalized to untreated control. Each histamine treatment 
time point was then normalized to its own vehicle control. 
 
 
corresponds to threonine 505 (T505) in hKv7.5. In order to determine if 
phosphorylation of T505 is necessary for histamine-induced hKv7.5 current 
inhibition, a vector was previously created to drive expression of a mutant hKv7.5 
in which T505 was replaced by alanine (T505A). Treatment with histamine (1 µM) 
and PMA (1 nM) still resulted in significant inhibition of hKv7.5 currents (17.5 ± 
6.7% and 52.6 ± 7.6%, respectively, Figure 11A, C) at -20mV. Although it appeared 
as if histamine suppressed mutant T505A currents to a lesser extent compared to 





There was also no significant difference between WT and T505A channels in the 
amount of current inhibition at -20 mV for PMA (Figure 11D). These results indicate 
that this particular amino acid residue may be necessary for the regulation of 
hKv7.5 currents by histamine, however current results are inconclusive. 
 
Serine Residue 441 is Necessary for Regulation of hKv7.5 Current by 
Histamine, but not for Channel Phosphorylation.  
MIT NEW Scansite 3 software predicted that hKv7.5 serine residue 441 
(S441) to be a potential PKCα phosphorylation site, a residue that also happens 
to fall within the recognition sequence for the anti-phosphoserine antibody used in 
our previous studies examining hKv7.5 channel phosphorylation following 
histamine treatment. In order to determine if S441 phosphorylation is required for 
hKv7.5 current inhibition and channel phosphorylation following treatment with 
histamine and PMA, a vector was constructed that would drive the expression of 
a nonphosphorylatable mutant hKv7.5 in which S441 was replaced by alanine 
(S441A). PMA still significantly inhibited hKv7.5-S441A currents (63.0 ± 7.5% at -
20 mV, Figure 12C, D), however histamine was unable to suppress hKv7.5-S441A 
currents (Figure 12A, B). Despite the lack of histamine-induced hKv7.5-S441A 
current suppression, a significant increase in hKv7.5-S441A channel 
phosphorylation was observed upon treatment with either histamine or PMA (1.72 






Figure 9. PKCα is necessary for histamine-induced inhibition of hKv7.5 
currents and histamine-induced sustained increases in [Ca2+]cyt in cultured 
HTSMCs. (A) I-V curves of steady state currents through hKv7.5 channels 
recorded in cultured HTSMCs lacking PKCα before (filled circles) and after 
treatment with histamine (1 µM, open circles, n=5). (B) I-V curves of steady state 
currents through hKv7.5 channels recorded in cultured HTSMCs expressing 
scrambled control shRNA before (filled circles) and after treatment with histamine 
(1 µM, open circles, n=4). (C) Averaged time courses of [Ca2+]cyt following 
treatment of cultured HTSMCs lacking shPKCα (open circles) or expressing 
scrambled control shRNA (closed circles) with histamine (1 µM, n=12). (B) 
Summary of 3 experiments (triplicate wells). Data shows average [Ca2+]cyt for the 
final 10-15 minutes of treatment (“sustained” [Ca2+]cyt increases) with histamine in 
cultured HTSMCs lacking shPKCα (white bar) or expressing scrambled control 
shRNA (black bar). *, significant difference from control, p < 0.05, paired t-test. ‡, 
significant difference from indicated groups, p < 0.05, one way ANOVA followed 
by Holm-Sidak post hoc test, with multiple comparisons among all groups. 
 
 
Preliminary Mass Spectrometry Results are Inconclusive. 
Results thus far implicate S441 as necessary for histamine-induced hKv7.5 
current suppression, though immunoprecipitation studies suggest that there are 





treatment with histamine. Serine residue 385 (S385) is a putative PKCα 
phosphorylation site and also falls within the recognition motif for the anti-
phosphoserine antibody (-K/R-X-S-FILVY-K/R-) and might contribute to the 
remaining signal detected when S441 was mutated to alanine. MIT NEW Scansite 
3 also identifies serine residue 772 (S772) as a putative PKC phosphorylation site, 
however this particular amino acid does not fall within the recognition motif for the 
antibody used. 
Our initial mass spectrometry analysis was inconclusive due to low sample 
concentration and digestion with trypsin not producing fragments with the amino 
acid residues of interest. Our second preliminary mass spectrometry results 
indicated that in the EndoQ digested samples for hKv7.5-WT and hKv7.5-S441A 
channels, treatment with histamine (1 µM) induced phosphorylation of S385 and 
this phosphorylation was not present in untreated samples or samples that had 
been pretreated with the PKC inhibitor Ro-31-8220 (1 µM). No S385 
phosphorylation was observed in hKv7.5-T505A expressing HTSMCs. 
Interestingly, in the same samples digested with EndoK, all samples showed 
phosphorylation at S385. 
S772 phosphorylation was also observed in nearly all samples from both 
EndoQ and EndoK digestions, except for the  EndoQ hKv7.5-WT untreated sample 
and the hKv7.5-S441A Ro-31-8220 pretreated sample.  
A new site not predicted by MIT NEW Scansite 3 software, serine residue 







Figure 10. PKCα is not necessary for histamine-induced increases in hKv7.5 
channel phosphorylation in cultured HTSMCs. (A) Representative western blot 
of FLAG immunoprecipitates from cultured HTSMCs overexpressing FLAG-
hKv7.5 channels that expressed scrambled control shRNA or shRNA against 
PKCα and were left untreated or treated with histamine (1 µM, 1 minute) probed 
with an anti-phosphoserine PKC substrate antibody (top). The same membrane 
was probed with an anti-FLAG antibody to serve as a loading control (second from 
top). Whole cell lysates (50 µg) were run separately and probed with an anti-PKCα 
antibody to confirm PKCα knockdown (second from bottom) and an anti-GAPDH 
antibody to serve as a loading control (bottom). (B) Densitometry summarized from 
5 experiments. *, significant difference from control, p < 0.05, independent t-test 
followed by Mann-Whitney U rank sum test. 
 
 
treated sample and hKv7.5-S441A histamine and Ro-31-8220 plus histamine 








No phosphorylation at T505 was observed in any samples that contained 
an observable fragment, and no fragment containing S441 was analyzed despite 
our enzyme selection. 
Due to the discrepancies between EndoQ and EndoK samples and the 
different phosphorylation patterns that were observed (Table 1), it is important to 
repeat these studies before any conclusions can be made. 
 
Retigabine Dose-dependently Relaxes Rat Airways Preconstricted with 
Methacholine. 
We have demonstrated on multiple occasions that bronchoconstrictor 
agonists suppress Kv7 currents in ASMCs (Brueggemann, Kakad et al. 2012, 
Haick, Brueggemann et al. 2017). We also observed that the Kv7 channel activator 
flupirtine can attenuate histamine-induced bronchoconstriction and that inhibiting 
Kv7 channels with XE991 is sufficient to induce robust constriction of human 
airways (Brueggemann, Kakad et al. 2012). These observations led us to 
hypothesize that Kv7 channel activators represent a novel class of bronchodilators 
that may be used in the treatment of asthma.  
PCLS were used as an experimental model to further assess the functional 
consequences of Kv7 channel manipulation in airway smooth muscle. This in vitro 
system allows the user to visualize and monitor the responses of individual airways 
to various treatments while allowing for the preservation of cellular processes 
within the tissue system and can be used with essentially any mammalian species, 






Figure 11. Threonine 505 may be necessary for histamine-induced 
suppression of hKv7.5 currents in cultured HTSMCs. (A) I-V curves of steady 
state currents through hKv7.5-T505A channels recorded in cultured HTSMCs 
before (filled circles) and after treatment with histamine (1 µM, open circles, n=7). 
(B) Summarized data shows average hKv7.5 current at -20 mV under control 
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with 
histamine (1 µM, dark grey bar, n=6), or following treatment of hKv7.5-T505A 
expressing HTSMCs with histamine (1 µM, light great bar, n=7). (C) I-V curves of 
steady state currents through hKv7.5-T505A channels recorded in cultured 
HTSMCs before (filled circles) and after treatment with PMA (1 nM, open circles, 
n=7). (D) Summarized data shows average hKv7.5 current at -20 mV under control 
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with 
PMA (1 nM, dark grey bar, n=4), or following treatment of hKv7.5-T505A 
expressing HTSMCs with PMA (1 nM, light great bar, n=7). *, significantly different 
from control, p < 0.05, paired t-test. #, significant difference from indicated groups, 
p < 0.05, one way ANOVA on RANKS followed by Dunn’s post hoc analysis, with 








Figure 12. Serine 441 is necessary for histamine- but not PMA-induced 
inhibition of hKv7.5 currents in cultured HTSMCs. (A) I-V curves of steady state 
currents through hKv7.5-S441A channels recorded in cultured HTSMCs before 
(filled circles) and after treatment with histamine (1 µM, open circles, n=9). (B) 
Summarized data shows average hKv7.5 current at -20 mV under control 
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with 
histamine (1 µM, dark grey bar, n=6), or following treatment of hKv7.5-S441A 
expressing HTSMCs with histamine (1 µM, light great bar, n=9). (C) I-V curves of 
steady state currents through hKv7.5-S441A channels recorded in cultured 
HTSMCs before (filled circles) and after treatment with PMA (1 nM, open circles, 
n=6). (D) Summarized data shows average hKv7.5 current at -20 mV under control 
conditions (black bar), following treatment of hKv7.5-WT expressing HTSMCs with 
PMA (1 nM, dark grey bar, n=4), or following treatment of hKv7.5-T505A 
expressing HTSMCs with PMA (1 nM, light great bar, n=6). *, significantly different 
from control, p < 0.05, paired t-test. #, significant difference from indicated groups, 
p < 0.05, one way ANOVA on RANKS followed by Dunn’s post hoc analysis, with 
multiple comparisons among all groups. ‡, significant difference from indicated 
groups, p < 0.05, one way ANOVA followed by Holm-Sidak post hoc test, with 








Figure 13. Serine 441 is not necessary for histamine- or PMA- induced 
phosphorylation of hKv7.5 channels in cultured HTSMCs. (A) Representative 
western blot of FLAG immunoprecipitates from cultured HTSMCs overexpressing 
FLAG-hKv7.5-WT or FLAG-hKv7.5-S441A channels that were left untreated, 
treated with histamine (1 µM, 1 minute), or treated with PMA (1 nM, 30 minutes) 
probed with an anti-phosphoserine PKC substrate antibody (top). The same 
membrane was probed with an anti-FLAG antibody to serve as a loading control 
(bottom). (B) Densitometry summarized from 5 experiments. *, significant 
difference from indicated columns, p < 0.05, one-way ANOVA followed by Holm-
Sidak post hoc test, with multiple comparisons versus control group. 
 
 
(Liberati, Randle et al. 2010, Sanderson 2011). Retigabine dose-dependently 
relaxed rat airways preconstricted with 230 nM methacholine, the approximate 
EC50 for methacholine in rat airways (Brueggemann, Haick et al. 2014) (EC50=3.6 
± 0.3 µM; maximum relaxation 61  9%, Figure 14B). Retigabine-induced 











Table 1. Preliminary Mass Spectrometry Results. Phosphorylation sites of 
interest on hKv7.5 channels. HTSMCs expressing FLAG-hKv7.5-WT, FLAG-
hKv7.5-S441A, or FLAG-hKv7.5-T505A channels were left untreated, treated with 
1 µM histamine for 1 minute, or pretreated with 1 µM Ro-30-8220 for 1 hour prior 
to treatment with 1 µM histamine prior to immunoprecipitation with an anti-FLAG 
antibody. Each sample was digested with EndoK (“K”) and EndoQ (“Q) and 
subjected to mass spectrometry analysis. K or Q identifies residues where 
phosphorylation was detected for each enzymatic digest. 
 
 
Formoterol Dose-dependently Relaxes Rat Airways Preconstricted with 
Methacholine. 
 Formoterol is a commonly prescribed LABA that is typically used for 
“maintenance” therapy, but also produces rapid and effective bronchodilation 
during acute asthma attacks (Rodrigo, Neffen et al. 2010, Ricciardolo, Blasi et al. 
2015). Similar to retigabine, formoterol dose-dependently relaxed rat airways 
preconstricted with 230 nM methacholine (EC50=2.4 ± 0.3 nM; maximum relaxation 
72  5%, Figure 15B), however there was a substantial time-dependent decline in 









Figure 14. Retigabine dose-dependently relaxes rat airways preconstricted 
with methacholine. (B) Representative time course depicting the changes in area 
of a single rat airway (pictured in (A)) treated with methacholine (230 nM, 30 
minutes), followed by retigabine (10 µM) in the continued presence of 
methacholine (30 minutes), and then washed. (C) Averaged dose-response curve 
of retigabine-induced relaxation of rat airways preconstricted with methacholine 
(230 nM) fitted to the Hill equation (n=6). 
 
 
Retigabine Enhances Formoterol-induced Relaxation of Rat Airways 
Preconstricted with Methacholine.  
 Airways were constricted with 230 nM methacholine and then a submaximal 
concentration of retigabine (10 µM) was included with the different increasing 
concentrations of formoterol (Figure 16A). The addition of retigabine increased 
both the maximal and the sustained airway relaxation compared to formoterol 
alone (Figure 16B) and also significantly decreased the time-dependent decline in 





 The time-dependent decline in airway relaxation, or “desensitization”, to 
formoterol treatment was of particular interest and warranted further investigation. 
There is considerable evidence that regular use of long-acting β2-agonists, such 
as salmeterol or formoterol, for the treatment of asthma, results in the development  
of tolerance and reduced efficacy. When formoterol (10 nM) was used repetitively 
as a bronchodilator on a single airway, a time-dependent decline in relaxation was 
observed during each consecutive application and there was also an overall 
decrease in the final extent of relaxation achieved following successive formoterol 
applications (Figure 17A). The initial maximum relaxation peaked at 68 ± 10% and 
tapered significantly to a final relaxation of 46 ± 14% after 30 minutes. The second 
application of formoterol reached a maximum relaxation of only 48 ± 8% and 
declined to a final relaxation of 32 ± 6% after 30 minutes (Figure 17C). Adding 
retigabine (10 µM) to the second application of formoterol resulted in significantly 
greater relaxation (72 ± 8%, maximum and final relaxation, Figure 17B, D) and 
there was no time-dependent decline in relaxation after 30 minutes.  
 
Retigabine Appears to Enhance Formoterol-induced Relaxation of Human 
Airways Preconstricted with Histamine. 
 Formoterol (10 pM) was applied repetitively to human airways constricted 
with 50 nM histamine. Although a time-dependent decline in formoterol-induced 
relaxation was not observed, the second consecutive application of formoterol 







Figure 15. Formoterol dose-dependently relaxes rat airways preconstricted 
with methacholine. (B) Representative time course depicting the changes in area 
of a single rat airway (pictured in (A)) treated with methacholine (230 nM, 30 
minutes), followed by formoterol (10 nM) in the continued presence of 
methacholine (30 minutes), and then washed. (C) Averaged dose-response curve 
of maximum formoterol-induced relaxation of rat airways preconstricted with 
methacholine (230 nM) fitted to the Hill equation (n=6). 
 
 
relaxation, respectively, Figure 18A, C). When retigabine (10 µM) is included with 
the second application of formoterol, airways relax to a greater extent than the 
initial formoterol treatment (28 ± 6.7% and 58 ± 16.9%, respectively, Figure 18B, 
C). While retigabine’s ability to enhance formoterol-induced airway relaxation is 
approaching significance, additional studies are required before any conclusions 






Retigabine Relaxes OVA-sensitized Guinea Pig Airways Preconstricted with 
Methacholine. 
 Results thus far indicate that retigabine is an effective bronchodilator in 
normal rat and human airways, however it is necessary to determine if retigabine 
retains its bronchodilatory effects in asthmatic airways. Seeing as the availability 
of human tissue, particularly asthmatic tissue, can be limited, it is beneficial to have 
an animal model system that is comparable to human. The guinea pig model of 
allergic asthma is commonly used to observe and test airway hyperresponsiveness 
(Meurs, Gosens et al. 2008, McGovern and Mazzone 2014). PCLS prepared from 
guinea pigs are considered to be a more appropriate model than rat or mouse 
(Ressmeyer, Larsson et al. 2006) and the late asthmatic responses and immediate 
hypersensitivity to irritants following sensitization in guinea pigs are comparable to 
the human allergic response (Meurs, Gosens et al. 2008). 
 Our laboratory has adopted a guinea pig OVA-sensitization protocol that 
consistently induces asthma-like symptoms upon exposure to nebulized OVA. 
Briefly, male Hartley guinea pigs are given 3 intraperitoneal injections of OVA or 
saline (control) on days 1, 3 and 5. Following a 2 week sensitization period, the 
animals are exposed on 3 successive days to a fine mist of OVA for 30 minutes 
while being monitored for symptoms such as chewing, labored breathing, 
coughing, and gasping. Tissues are collected post-euthanasia for PCLS. OVA 







Figure 16. Retigabine enhances formoterol-induced relaxation of rat airways 
preconstricted with methacholine. (A) Representative time course depicting the 
changes in area of a single rat airway treated with methacholine (230 nM, 30 
minutes), followed by formoterol (10 nM) plus retigabine (10 µM) in the continued 
presence of methacholine (30 minutes), and then washed. (B) Summarized bar 
graph depicting the maximum (solid bars) and final (checkered bars) amount of 
formoterol (blue bars) versus formoterol plus retigabine (10 µM, green bars) 
induced relaxation of rat airways preconstricted with methacholine (230 nM) (n=6). 
(C) Summarized bar graph depicting formoterol (blue striped bars) versus 
formoterol plus retigabine (10 µM, green striped bars) maximum minus final 
relaxation, or the total time-dependent decline in relaxation during the 30 minute 







Figure 17. Retigabine attenuates the time-dependent decline in formoterol-
induced relaxation of rat airways preconstricted with methacholine observed 
upon repetitive administration.  (A) Representative time course depicting the 
changes in area of a single rat airway treated with methacholine (230 nM, 30 
minutes), followed by formoterol (10 nM) in the continued presence of 
methacholine (30 minutes), with a 45 minute washout period between 
methacholine-induced constrictions. (B) Representative time course depicting the 
changes in area of a single rat airway treated with methacholine (230 nM, 30 
minutes), followed by formoterol (10 nM) or formoterol (10 nM) plus retigabine (10 
µM) in the continued presence of methacholine (30 minutes), with a 45 minute 
washout period between methacholine-induced constrictions. (C) Summarized bar 
graph depicting the average maximum and final relaxation of airways for each 
application of formoterol, from experiments depicted in A (n=6). (D) Summarized 
bar graph depicting the average maximum and final relaxation of airways for 
formoterol and formoterol plus retigabine, from experiments depicted in B (n=6). *, 
significant difference from max1, p < 0.05, one way repeated measures ANOVA. 







Figure 18. Retigabine appears to attenuate the time-dependent decline in 
formoterol-induced relaxation of human airways preconstricted with 
histamine observed upon repetitive administration. (A) Representative time 
course depicting the changes in area of a single human airway treated with 
histamine (50 nM, 30 minutes), followed by formoterol (10 pM) in the continued 
presence of histamine (30 minutes), with a 45 minute washout period between 
histamine-induced constrictions. (B) Representative time course depicting the 
changes in area of a single human airway treated with histamine (50 nM, 30 
minutes), followed by formoterol (10 pM) or formoterol (10 pM) plus retigabine (10 
µM) in the continued presence of histamine (30 minutes), with a 45 minute washout 
period between histamine-induced constrictions. (C) Summarized bar graph 
depicting the average repetitive formoterol induced relaxation or formoterol then 
formoterol plus retigabine induced relaxation of human airways (n=5). 
 
 
animals and PCLS from OVA-sensitized animals show increased sensitivity to the 
bronchoconstrictor agonists methacholine and histamine (Kakad 2012). 
 100 nM methacholine (the approximate EC50 in control guinea pig airways, 





with 30 µM retigabine (the concentration used in our asthmatic human PCLS 
experiment) in the presence of methacholine. Treatment with retigabine produced 
significant airway relaxation (32 ± 8.3%, Figure 19A, C). Retigabine vehicle did not 
significantly relax airways (Figure 19B, D). Similar results were observed for OVA-
sensitized guinea pig airways (29 ± 5.8% relaxation, Figure 20). 
 
Retigabine Attenuates OVA-induced Allergic Asthma Symptoms in OVA- 
Sensitized Guinea Pigs. 
 A set of pilot studies were completed to determine if retigabine was capable 
of attenuating the allergic asthma symptoms displayed by OVA-sensitized guinea 
pigs during the nebulized OVA challenges. When the unanaesthetized guinea pig 
was exposed to nebulized OVA alone, symptoms such as coughing and rapid, 
labored breathing, occurred within minutes. The animal was rescued from the 
chamber when the symptoms become too severe, approximately 15 minutes into 
the 30 minute challenge. Once removed from the chamber, the guinea pig was 
weak and lethargic, requiring a monitored recovery period. When retigabine (1 
mM) was included with the nebulized OVA, the same guinea pig did not develop 
symptoms until approximately 18-22 minutes into the challenge and the symptoms 
were not nearly as severe as those observed with nebulized OVA alone. The 
animal withstood the entire 30 minute challenge and was alert once removed from 
the chamber. A parallel study was completed with control guinea pigs that showed 







Figure 19. Retigabine relaxes control guinea pig airways preconstricted with 
methacholine. (A) Representative time course depicting the changes in area of a 
single guinea pig airway treated with methacholine (100 nM, 30 minutes), then 
retigabine (30 µM) in the continued presence of methacholine (45 minutes), 
followed by removal of retigabine (30 minutes) and washout. (B) Representative 
time course depicting the changes in area of a single guinea pig airway treated 
with methacholine (100 nM, 30 minutes), then retigabine vehicle in the continued 
presence of methacholine (45 minutes), followed by removal of retigabine vehicle 
(30 minutes) and washout.  (C) Summarized bar graph depicting average airway 
area relative to control (black bar, average of 5 minutes before methacholine 
treatment) upon treatment with methacholine (100 nM, grey bar), methacholine 
and retigabine (30 µM, yellow bar), and removal of retigabine (grey bar) from 
experiments depicted in A. (D) Summarized bar graph depicting average airway 
area relative to control (black bar, average of 5 minutes before methacholine 
treatment) upon treatment with methacholine (100 nM, grey bar), methacholine 
and retigabine vehicle (grey bar), and removal of retigabine vehicle (grey bar) from 
experiments depicted in B. *, significant difference, p < 0.05, one way ANOVA 






Figure 20. Retigabine relaxes OVA-sensitized guinea pig airways 
preconstricted with methacholine. (A) Representative time course depicting the 
changes in area of a single guinea pig airway treated with methacholine (100 nM, 
30 minutes), then retigabine (30 µM) in the continued presence of methacholine 
(45 minutes), followed by removal of retigabine (30 minutes) and washout. (B) 
Representative time course depicting the changes in area of a single guinea pig 
airway treated with methacholine (100 nM, 30 minutes), then retigabine vehicle in 
the continued presence of methacholine (45 minutes), followed by removal of 
retigabine vehicle (30 minutes) and washout.  (C) Summarized bar graph depicting 
average airway area relative to control (black bar, average of 5 minutes before 
methacholine treatment) upon treatment with methacholine (100 nM, grey bar), 
methacholine and retigabine (30 µM, yellow bar), and removal of retigabine (grey 
bar) from experiments depicted in A. (D) Summarized bar graph depicting average 
airway area relative to control (black bar, average of 5 minutes before 
methacholine treatment) upon treatment with methacholine (100 nM, grey bar), 
methacholine and retigabine vehicle (grey bar), and removal of retigabine vehicle 
(grey bar) from experiments depicted in B. *, significant difference, p < 0.05, one 





Guinea Pig flexiVent Optimization Experiments and Troubleshooting. 
 The results from our PCLS experiments and the nebulized retigabine pilot 
studies suggest that activating Kv7 channels represents a novel approach to 
asthma therapy. Our next goal was to quantitatively examine the bronchodilatory 
effects of retigabine using an in vivo approach. Naïve guinea pigs were 
mechanically ventilated while under anesthesia and a variety of respiratory 
parameters, such as respiratory resistance, Newtonian resistance, tissue 
dampening, and tissue elastance, were measured using a small animal ventilator 
called a flexiVent controlled by flexiWare software. Once a stable baseline 
respiratory resistance value was obtained, the animals were given i.v. or nebulized 
histamine or methacholine at approximately 5 minute intervals. Following each 
administration of bronchoconstrictor, respiratory parameters were recorded using 
the series of “snapshot” and “quick prime-6” maneuvers during the 5 minute 
interval. 
A variety of experimental approaches were attempted during this 
optimization study on naïve guinea pigs with the hopes to establish a protocol that 
could be used to determine if nebulized Kv7 channel activators were capable of 
attenuating the increase in respiratory resistance observed upon 
bronchoconstrictor agonist treatment. Each experiment typically began with 
establishing a dose-response for the i.v. or nebulized bronchoconstrictor. In some 
instances we would repeat the dose-response to examine the reproducibility in the 







Figure 21. Repetitive intravenous histamine with increasing concentrations 
of nebulized retigabine. Representative experiment depicting respiratory 
resistance measured in an anesthetized and mechanically ventilated following the 
indicated treatments. Vehicle (water) or increasing concentrations of retigabine (1-
10 mM) were nebulized prior to each intravenous injection of histamine (2 µg/kg). 
Respiratory resistance was determined using the flexiWare “snapshot” maneuver 
following histamine injection.   
 
 
observed increased sensitivity to the bronchoconstrictor agonist following multiple 
applications. After establishing a dose-response, we selected an approximate 
EC50 dose and tested for reproducibility upon multiple administrations. The multiple 
i.v. approximate EC50 doses tended to be more reproducible than multiple 
nebulized approximate EC50 doses. The addition of nebulized Kv7 channel 
activator (1, 5, or 10 mM retigabine, 10 mM flupirtine, 1 or 10 mM ML213) with 
either i.v. or nebulized bronchoconstrictor did not have an appreciable effect on 
the increases in respiratory resistance. There was one instance where nebulized 
1, 5, and 10 mM retigabine attenuated the increase in respiratory resistance 





21), however the second and third doses resulted in an increase in respiratory 
resistance comparable to histamine alone despite nebulizing retigabine prior to 
each i.v. administration. We were able to establish a positive control, 28 µM 
nebulized formoterol, which consistently attenuated the increased respiratory 
resistance observed following bronchoconstrictor agonist treatment. 
We decided to try a different approach for the remainder of our approved 
optimization experiments. First, we would limit the nebulized bronchoconstrictor 
dose-response so that respiratory resistance only increased to 2-3 times over the 
initial baseline. This way we were not working with too high of a bronchoconstrictor 
concentration to observe any protective effects offered by the Kv7 channel 
activators. We also decided to add a nebulized Kv7 channel activator pretreatment 
period that attempted to mimic the extended exposure to retigabine during our pilot 
studies (see Retigabine attenuates OVA-induced allergic asthma symptoms in 
guinea pigs). Following the establishment of a dose-response, retigabine would be 
nebulized approximately every minute for an extended period of time (initially 30 
minutes, but we decreased the time to 18 minutes to avoid potential 
fluid/obstruction buildup associated with prolonged nebulization), and this 
pretreatment period would also include deep breaths to ensure that retigabine was 
reaching the airways. A second dose-response would then be completed to 
determine if the Kv7 channel activator attenuated the observed increases in 
respiratory resistance. When the vehicle for retigabine, water, was nebulized 







Figure 22. Repetitive nebulized methacholine dose response with nebulized 
retigabine pretreatment. Representative experiment depicting respiratory 
resistance measured in an anesthetized and mechanically ventilated following the 
indicated treatments. Vehicle (water) or retigabine (1 mM) was nebulized 
approximately every minute for 18 minutes in between treatment with increasing 
doses of nebulized methacholine (0.0-0.3 mg/ml). Respiratory resistance was 
determined using the flexiWare “snapshot” maneuver. 
 
 
resistance dose-response. Unfortunately, we also did not observe any protective 
effects of retigabine following pretreatment (Figure 22). There was a single 
instance where pretreating with 10 mM retigabine and including 10 mM retigabine 
in the second methacholine dose-response appeared to attenuate the increase in 
respiratory resistance, however we were unable to repeat this result by the 
conclusion of our allotted optimization experiments. An interesting and consistent 
result was the lowering of respiratory resistance compared to the initial baseline 
respiratory resistance following the retigabine pretreatment period (Figure 23). 
Although these optimization experiments indicate that retigabine is not offering 
protection against bronchoconstrictor agonist-induced increases in respiratory 






Figure 23. Nebulized retigabine lowers baseline respiratory resistance. 
Depiction of the average respiratory resistance values measured using the 
flexiWare “snapshot” maneuver during the vehicle (water) or retigabine (10 mM) 
“pretreatment” nebulizing period. Values were normalized to the initial baseline 
resistance for each animal. *, significant difference, p < 0.05, student’s t-test.  
 
nebulized retigabine. Additional studies to establish a protocol examining the 
therapeutic potential of Kv7 channel activators in vivo would need to be completed 















Our previous examination of ASMCs revealed the presence of Kv7 K+ 
currents that were inhibited upon treatment of the cells with bronchoconstrictor 
agonists. Inhibition of Kv7 channels with the specific blocker XE991 was sufficient 
to induce constriction of human airways, and this inhibition was reversed upon 
blocking L-type VSCCs with verapamil. Lastly, activation of Kv7 channels 
attenuated histamine-induced constriction of human airways (Brueggemann, 
Kakad et al. 2012). These results highlighted the importance of Kv7 channels in 
the regulation of airway smooth muscle tone, however additional studies would be 
necessary to clarify the specifics of this role and to examine the therapeutic 
potential of targeting Kv7 channels for bronchodilator therapy. 
The work presented in this dissertation aimed to (1) elucidate the 
mechanism by which the bronchoconstrictor agonist histamine regulates Kv7 
channels in airway smooth muscle and (2) determine the efficacy of Kv7 channel 
activators in attenuating agonist-induced bronchoconstriction and explore their 
therapeutic potential for the treatment of asthma. Experiments completed in 
parallel with this project outlined in this dissertation revealed that the 
bronchoconstrictor agonist histamine enhanced phosphorylation of endogenous 
Kv7.5 channels in freshly isolated human trachealis smooth muscle and inhibited 





Using low-passage cultured HTSMCs as an expression system, we 
determined that activation of PKC, both directly with PMA or indirectly with 
histamine, increased phosphorylation of hKv7.5 channels (Figure 7) and inhibited 
hKv7.5 currents (Figure 4). The effects of histamine on the phosphorylation status 
of the channels and on the inhibition of hKv7.5 currents occurred in a PKC-
dependent manner, evidenced by an attenuation of hKv7.5 phosphorylation and 
current inhibition when PKC was inhibited prior to histamine treatment (Figure 7, 
5). The regulation of hKv7.5 currents by histamine appears to be dependent on 
PKCα specifically (Figure 9), as well as a serine residue located at position 441 
(Figure 12). Surprisingly the loss of PKCα or the mutation of serine 441 to alanine 
did not attenuate histamine-induced phosphorylation of hKv7.5 channels (Figure 
10, 13) even though it prevented histamine-induced regulation of hKv7.5 currents. 
We also provide evidence that illustrated the ability of Kv7 channel activation to 
relax rat, guinea pig, and human airways that had been constricted with 
bronchoconstrictor agonists and highlight a promising and novel therapeutic 
approach to treat asthma that should continue to be investigated.  
The suppression of Kv7 currents following Gq-coupled receptor activation 
has been extensively examined in neurons (Marrion 1997, Delmas and Brown 
2005) and more recently in vascular smooth muscle (Mackie, Brueggemann et al. 
2008, Mani, O'Dowd et al. 2013, Brueggemann, Mackie et al. 2014). As mentioned 
in chapter 2, PKC is one common effector of Gq-coupled agonist-induced inhibition 





suppression of Kv7 currents in airway smooth muscle has not been investigated 
until now. PKC is also an established regulator of ASMC contraction and airway 
constriction (Webb, Hirst et al. 2000). Evidence suggests that phosphorylation of 
a variety of substrates, particularly those involved in the regulation of a cell’s 
contractile machinery (Pohl, Winder et al. 1997, Webb, Hirst et al. 2000, Sakai, 
Chiba et al. 2005), are responsible for the contractile effects of PKC activation. 
However, there is also a component of PKC-induced Ca2+ signaling in ASMCs and 
airway smooth muscle constriction that is dependent on extracellular Ca2+ and L-
type VSCCs (Park and Rasmussen 1985, Knox, Baldwin et al. 1993, Rossetti, 
Savineau et al. 1995, Yang and Black 1996, Mukherjee, Trice et al. 2013) that 
cannot be explained by phosphorylation of the previously identified targets. Results 
presented in this dissertation have also highlighted the importance of L-type 
VSCCs in the sustained [Ca2+]cyt elevation observed following treatment of 
HTSMCs with histamine (Figure 3). Evidence suggests that inhibition of Kv7 
channels in vascular smooth muscle results in membrane depolarization that 
promotes the activation of L-type VSCCs (Mackie, Brueggemann et al. 2008). We 
have established that histamine inhibits Kv7 channels in ASMCs (Brueggemann, 
Kakad et al. 2012) and upon completion of this project have determined that this 
occurs in a PKC-dependent manner. We have also demonstrated that inhibition of 
Kv7 currents is sufficient to depolarize ASMC membranes (Haick, Brueggemann 
et al. 2017). Therefore, it is reasonable to predict that the L-type VSCC-dependent 





muscle may be occurring, at least in part, as a result of inhibition of Kv7 channels 
(Figure 24). 
 Multiple PKC isoforms have been found to be expressed in ASMCs (Webb, 
Lindsay et al. 1997, Sakai, Yamamoto et al. 2009), however the specific isoform(s) 
behind the PKC-dependent effects observed in airway smooth muscle have yet to 
be identified (Webb, Hirst et al. 2000). PKCα was a particularly promising 
candidate for the histamine-induced phosphorylation of hKv7.5 channels and 
inhibition of their currents. In vascular smooth muscle, histamine treatment 
resulted in redistribution of PKC activity from the cytosol to the plasma membrane 
(Haller, Smallwood et al. 1990) and PKCα specifically has been implicated in the 
phosphorylation of vascular smooth muscle contractile proteins and phorbol ester-
induced constriction of rabbit femoral arteries (Eto, Kitazawa et al. 2001). 
Histamine treatment has also been demonstrated to induce PKCα translocation 
from cytosol to membranes in a HeLa cell expression system (Rimessi, Rizzuto et 
al. 2007) and in CHO-H1 cells (Megson, Walker et al. 2001). Indeed, PKCα was 
found to be necessary for histamine-induced inhibition of hKv7.5 currents in 
cultured HTSMCs (Figure 9). However, when we measured total phosphorylation 
with an anti-phosphoserine PKC substrate antibody, we still observed a significant 
increase in histamine-induced phosphorylation of hKv7.5 channels (Figure 10). 
Although this result was unexpected, all PKC isoforms except γ have been 
detected in cultured human ASMCs (Carlin, Yang et al. 1999) and it is possible 







Figure 24. Proposed role of Kv7 channels and L-type VSCCs following Gq-
coupled receptor signaling in ASMCs. ASMC contraction has a voltage-
dependent component of Ca2+ influx necessary for sustained contraction 
evidenced to occur through L-type voltage sensitive Ca2+ channels (VSCC). We 
hypothesize that the stimulus for the membrane depolarization necessary for L-
type VSCC activation occurs via PKC-dependent suppression of Kv7 currents, 
highlighted in grey. We hypothesize that the stimulus for the membrane 
depolarization necessary for L-type VSCC activation occurs via PKC-dependent 
suppression of Kv7 currents, highlighted in grey.  
 
 
isoforms that phosphorylate hKv7.5 channels. It is important to note that PKCα 
specifically is necessary for histamine-induced suppression of hKv7.5 currents in 
HTSMCs and that any additional phosphorylation by other PKC isoforms is likely 
unrelated to histamine-induced effects on hKv7.5 currents.  
 Repeating the immunoprecipitation experiments with other PKC isoforms 





area of exploration that may elucidate additional PKC isoforms that phosphorylate 
hKv7.5 channels following histamine treatment. Examining the residues on hKv7.5 
that are phosphorylated in response histamine treatment of HTSMCs under normal 
conditions and comparing them to the same samples that lack PKCα, or other PKC 
isoforms, using mass spectrometry would also give important insight into not only 
which PKC isoforms phosphorylate hKv7.5 channels but also which amino acid 
residues are important in histamine-induced hKv7.5 regulation. 
 The work completed in this dissertation indicates that threonine residue 505, 
a residue that corresponds with rat Kv7.2 serine 534 that has been identified as a 
PKC phosphorylation site on that channel (Hoshi, Zhang et al. 2003), may also be 
required for histamine-induced suppression of hKv7.5 currents in ASMCs (Figure 
11). Results suggest that histamine was still able to significantly suppress the 
mutant hKv7.5 currents. It appears that histamine suppresses hKv7.5 T505A 
channels to a lesser extent, however a significant difference was not observed. 
Our laboratory has observed decreased sensitivity of hKv7.5 T505A mutant 
channels to AVP-induced current suppression in A7r5 cells (LI Brueggemann, 
unpublished), therefore it is possible that mutation of this residue results in the 
decreased sensitivity of hKv7.5 currents to histamine as well.  
Although the effect of T505 mutation was inconclusive, our results indicate 
that hKv7.5 residue serine 441 is absolutely necessary for histamine-induced 
suppression of hKv7.5 currents (Figure 12). This residue was selected due to its 





immunoprecipitation studies (-K/R-X-S-FILVY-K/R-). Mutation of S441 to non-
phosphorylatable alanine abolished histamine’s ability to inhibit hKv7.5 currents 
(Figure 12), but interestingly did not attenuate histamine-induced phosphorylation 
of hKv7.5 (Figure 13). This indicates that there are likely other hKv7.5 amino acid 
residues that are phosphorylated in response to treatment with histamine, however 
they do not appear to be necessary for histamine-induced regulation of hKv7.5 
currents. 
Serine 385 also matches the consensus motif recognized by the antibody 
and may contribute to the remaining signal detected in our immunoprecipitation 
studies when S441 was mutated to alanine. EndoQ digested mass spectrometry 
studies suggest that this may indeed be the case (Table 1), however the 
experiment must be repeated before any conclusions can be made considering 
the observation of S385 phosphorylation in all EndoK digested samples. One 
potentially interesting observation was the lack of S385 phosphorylation following 
histamine treatment of the EndoQ digested hKv7.5-T505A expressing HTSMCs. It 
would also be of interest to examine the levels of S441 phosphorylation in the 
hKv7.5-T505A mutant samples. Seeing as the T505A mutant channels may be 
less sensitive to regulation by histamine, perhaps sequential phosphorylation of 
amino acid residues (T505 then S385 and/or S441) is necessary for normal 
regulation of the channel by histamine. 
 Although the electrophysiology studies completed in this dissertation 





current suppression, confirmation of S441 phosphorylation, as well as 
identification of other amino acids that are phosphorylated following treatment with 
histamine, should be assessed by completing additional mass spectrometry 
studies. It is essential to find a protocol that will allow for segments containing S441 
to be analyzed, considering that the EndoQ and EndoK sample digestions proved 
unsuccessful in that regard. Re-examining S385 is also of particular interest due 
to the preliminary mass spectrometry results and the fact that this residue is 
recognized by the antibody used in all of our previous studies. 
 The framework for elucidating the mechanism of histamine-induced 
regulation of hKv7.5 channels has been completed in the work presented in this 
dissertation. Confirming what we have learned thus far, as well as answering the 
questions that remain with the proposed experiments, will aid in establishing a 
clearer pathway of bronchoconstrictor agonist-induced regulation of hKv7.5 
channels in HTSMCs.  
 The second portion of this project aimed to examine the ability of Kv7 
channel activators to attenuate agonist-induced bronchoconstriction and begin to 
determine their therapeutic potential for the treatment of asthma. First we used 
PCLS to examine the bronchodilatory capabilities of the clinically available Kv7 
channel activator retigabine and compared it to that of the LABA formoterol. 
Retigabine dose-dependently relaxed rat airways that were preconstricted with 
methacholine (Figure 14). Prolonged use of β2-agonists has been reported to result 





desensitization and leads to decreased sensitivity to bronchodilator therapy and 
ultimately poor symptom management (Cazzola, Page et al. 2013). This 
phenomenon was exhibited in our rat PCLS model: while formoterol was capable 
of relaxing preconstricted rat airways, there was a time-dependent decline in 
relaxation observed during the 30 minute treatment period (Figure 15) that had not 
been observed with retigabine treatment alone. Enhanced relaxation was 
observed for some concentrations of formoterol upon inclusion of a submaximal 
dose of retigabine and the time-dependent decline observed over the 30 minute 
treatment period was significantly reduced when compared to formoterol treatment 
alone (Figure 16). We decided to take advantage of the time-dependent 
desensitization observed upon formoterol treatment in our rat PCLS model and 
found that consecutive applications of formoterol to airways that had been 
reproducibly constricted with methacholine resulted in a similar occurrence (Figure 
17). When a submaximal concentration of retigabine was added to the second 
application of formoterol, there was no time-dependent decline in airway relaxation 
at the end of the 30 minute treatment period and the final airway relaxation was 
significantly greater than that achieved during the first application of formoterol 
alone (Figure 17).  
The effects observed combining retigabine and formoterol were not 
additive. One mechanism of airway relaxation following Gs-coupled receptor 
stimulation with LABAs occurs through the activation of BK channels and 





also expected to induce airway relaxation via membrane hyperpolarization. These 
two mechanisms may be somewhat redundant under normal conditions, however 
Kv7-channel induced membrane depolarization appears to substitute for the loss 
of BK-channel induced membrane hyperpolarization following the Gs-coupled 
receptor desensitization that occurs following prolonged β2-agonist treatment. 
Combination bronchodilator therapies, specifically a LABA combined with a  
muscarinic antagonist, have been associated with several benefits (Cazzola, Page 
et al. 2013). The results observed in rat and human airways highlight the potential 
of Kv7 channel activators, retigabine in particular, to act as a bronchodilator, either 
alone or in combination with currently available bronchodilator therapy. 
 Aside from a single experiment examining the ability of retigabine to 
enhance formoterol induced bronchodilation in a manner similar to figure 17 using 
PCLS prepared from asthmatic tissue, little has been done to confirm the ability of 
Kv7 channel activators to relax airways in as asthmatic state. The availability of 
human tissue, especially asthmatic human tissue, is quite limited, therefore it was 
important for us to adopt an animal model of allergic asthma. The guinea pig model 
of allergic asthma is commonly used to observe and test AHR (Meurs, Gosens et 
al. 2008, McGovern and Mazzone 2014). PCLS prepared from guinea pigs are 
often considered to be a more appropriate model than rat or mouse (Ressmeyer, 
Larsson et al. 2006) and the late asthmatic responses and immediate 
hypersensitivity to irritants following sensitization in guinea pigs are comparable to 





The OVA-sensitization guinea pig model we adopted yields PCLS from 
OVA-sensitized animals that are more sensitive to the bronchoconstrictor agonists 
methacholine and histamine, a classic manifestation of AHR, when compared to 
PCLS from control animals (Kakad 2012). It is also interesting to note a 
downregulation of Kv7 channel expression that was observed when comparing 
sensitized to control guinea pig ASMCs (Kakad 2012). Our initial studies using 
guinea pig PCLS were largely successful, however recent attempts to examine the 
ability of retigabine to relax airways preconstricted with methacholine presented 
more of a technical challenge. Despite the presence of the β2-agonist isoproterenol 
in many of the isolation solutions and media, airways often constricted following 
PCLS preparation, likely due to the substance P-induced postmortem constriction 
that occurs in guinea pig airways (Lai, Lamm et al. 1984, Lai and Cornett 1987). 
We also observed considerable variation in the sensitivity of the guinea pig airways 
to methacholine. Some airways would not respond while other airways from the 
same preparation, or even the same lobe, would completely occlude. Our previous 
experiences with PCLS preparations from rat or human tissues were more 
consistent and predictable.  
Despite these difficulties, a set of experiments comparing the ability of 
retigabine to relax guinea pig airways preconstricted with methacholine in control 
and OVA-sensitized tissues were completed (Figure 19, 20). Retigabine relaxed 
airways to a similar extent (approximately 30%) in both control and sensitized 





sensitized tissues (Kakad 2012), implying that targeting the remaining Kv7 
channels with retigabine is sufficient to induce airway relaxation. These results, 
combined with the study completed in asthmatic human tissue, are indicative of 
the ability of retigabine to relax diseased airways and provide additional support 
for Kv7 channels to act as therapeutic targets for the treatment of asthma.   
 Our in vitro results were promising and warranted further investigation. The 
guinea pig OVA-model allows us to test the effectiveness of retigabine as a 
bronchodilator in vivo as well. An initial pilot study examined the ability of retigabine 
to attenuate the asthma-like symptoms observed during nebulized OVA 
challenges with OVA-sensitized guinea pigs. The results provided the first 
evidence of the in vivo potential of Kv7 channel activators as novel asthma 
therapeutics. The presence of retigabine along with the nebulized OVA offered 
such substantial protection that only minor symptoms were observed towards the 
end of the 30 minute challenge period instead of the standard 7-8 minutes into the 
challenge observed with nebulized OVA alone. The OVA-sensitized guinea pig 
also lasted the entire 30 minutes of the challenge without having to be rescued 
from the chamber, as opposed to approximately 15 minutes typically observed with 
nebulized OVA alone. Upon removal from the chamber, the guinea pig was alert 
and active and did not require any monitored recovery time.  
These results were encouraging, but qualitative in nature. In order to 
quantitatively measure the bronchodilatory capabilities of retigabine in vivo, we 





ventilator. Our initial plan was to test if nebulized retigabine offered protection 
against the increases in respiratory resistance observed following 
bronchoconstrictor agonist treatment. In our first flexiVent optimization 
experiments, retigabine was nebulized directly prior to either nebulized or i.v. 
administration of bronchoconstrictor. There was only one instance where 
nebulized retigabine appeared to offer protection from i.v. histamine-induced 
increases in respiratory resistance (Figure 21), however this result was not 
reproducible, even in the same experiment. Similarly, retigabine did not offer 
protection from nebulized bronchoconstrictor challenge when nebulized prior to or 
in combination with the bronchoconstrictor. 
After our initial inconclusive results observed during the first portion of our 
optimization studies, we decided to adjust our protocol. First, we limited our 
bronchoconstrictor challenges to concentrations that induced an increase in 
respiratory resistance of only 2-3 times the initial baseline value. This would 
prevent us from using an agonist concentration that is too high and prevent 
unnecessary stress on the animal and its respiratory system. We also wanted to 
determine if keeping the bronchoconstrictor doses low would offer an improved 
chance of observing an attenuation of respiratory resistance increases following 
retigabine treatment. We also attempted to mimic the pilot studies as closely as 
possible. Our pilot study delivered a continuous mist of 1 mM retigabine in the 
presence of OVA to a consciously breathing animal. Unfortunately, the flexiVent is 





“pretreatment” regimen was developed in an attempt to deliver more retigabine to 
the airways. This “pretreatment” consisted of nebulizing vehicle (water) or 
retigabine approximately every minute for 18 minutes in between the nebulized 
bronchoconstrictor dose-response protocols. We also included deep breathes 
following each nebulization of retigabine in order to ensure that it was being 
delivered to the airways.  
Despite the changes made to the protocol, we did not observe protection 
against bronchoconstrictor-induced increases in respiratory resistance provided by 
nebulizing retigabine (Figure 22). In some instances nebulizing retigabine 
appeared to increase the sensitivity to bronchoconstrictor challenge, however this 
may be a result of the repetitive administration of the bronchoconstrictor and not 
necessarily due to the retigabine treatment. Another consideration is that both 
methacholine and histamine result in an increase in mucus secretion (Boat and 
Kleinerman 1975, Webber and Widdicombe 1987). This mucus secretion may 
result in airflow obstruction that is not always detectable using our current 
methods. In some instances the sinusoidal waveform produced during the 
“snapshot” maneuver may indicate the presence of an obstruction, however little 
can be done to remove that obstruction once it occurs. A different approach 
minimalizing bronchoconstrictor treatment may be considered to avoid this 
potential side effect, but we intended to use each animal as its own control for 






Although we did not observe consistent retigabine-induced protection 
during bronchoconstrictor challenges, nebulizing retigabine during the 
“pretreatment” period did lower respiratory resistance levels below the initial 
baseline levels recorded prior to the first bronchoconstrictor challenge (Figure 23). 
This suggests that retigabine is being delivered to the airways and is having some 
bronchodilatory effect, however the therapeutic relevance of this effect remains to 
be determined. 
Overall, our results indicate that activation of Kv7 channels represents a 
novel approach to bronchodilation in vitro, however developing an in vivo model to 
test the effectiveness of retigabine at relieving bronchoconstriction, particularly in 
asthmatic airways, is essential for the continuation of this project. One thing that 
may be important to note is that the initial optimization flexiVent studies utilized 
naïve guinea pigs; no OVA-sensitized guinea pigs were tested. It would be 
interesting to asses if retigabine offers protection to OVA-sensitized guinea pigs, 
either from their hypersensitivity to bronchoconstrictor agonists or from OVA-
induced bronchoconstriction. It is possible that retigabine may be effective at 
attenuating exaggerated responses to bronchoconstrictor agonists that are 
typically associated with this animal model (Kakad 2012). Our in vivo pilot study 
demonstrated the ability of retigabine to attenuate OVA-induced allergic responses 
typically observed in the unanesthetized OVA-sensitized guinea pigs. Perhaps 
retigabine would be effective at relieving the bronchoconstriction associated with 





suggests. The anesthetic used may also be interfering with our flexiVent studies. 
However, our pilot studies completed in conscious animals are more 
representative of the desired delivery method for retigabine (conscious, inhalation) 
and suggest the effectiveness of this drug at alleviating the symptoms associated 
with allergic asthma.   
The difficulties experienced with the guinea pig model imply that it may be 
beneficial to adopt a new model of allergic asthma to determine if Kv7 channel 
activators are efficacious bronchodilators. There are a number of different rat 
models that can be used to study asthma (Kucharewicz, Bodzenta-Lukaszyk et al. 
2008). Although Sprague Dawley rats, the species of rat used in our laboratory for 
PCLS experiments, do not develop an allergic reaction to OVA (Olivenstein, Renzi 
et al. 1993, Sirois and Bissonnette 2001), they can be used as a control group for 
Brown Norway OVA-sensitized rats (Careau and Bissonnette 2004). This would 
allow for a comparison of the bronchodilator effects of Kv7 channel activators to 
be compared more thoroughly in sensitized and non-sensitized rat airways. The 
difficulty we recently experienced using guinea pigs and guinea pig tissue, even in 
non-sensitized animals, only served to highlight the ease and reproducibility we 
observed when using rat tissue for previous studies. It would be interesting to see 
if this ease of use extends to sensitized rats and their tissue. There are also a 
variety of well-established mouse models (Nials and Uddin 2008, Shin, Takeda et 





activators that should be considered for addressing the potential of moving 
retigabine to clinical trials.  
 In summary, the bronchoconstrictor agonist histamine induces PKC-
dependent hKv7.5 channel phosphorylation and subsequent inhibition of hKv7.5 
currents in cultured human trachealis smooth muscle cells. PKCα appears to be 
necessary for current suppression by the bronchoconstrictor as well as partially 
necessary for sustained elevation of [Ca2+]cyt following treatment of HTSMCs with 
histamine. However, our biochemical analysis of phosphorylation of hKv7.5 by 
PKC indicates that additional PKC isoforms may also be phosphorylating the 
channel. Similarly, serine residue 441 appears to be necessary for histamine-
induced hKv7.5 current inhibition but our phosphorylation studies indicate that 
additional amino acid residues are also phosphorylated following histamine 
treatment, though these residues may not have an impact on the channel’s 
function. These findings, along with the other work presented in this dissertation, 
help to shed light on the ionic mechanisms involved in the regulation of airway 
smooth muscle contractility. 
 The bronchodilatory capacity of Kv7 channel activators was also explored. 
The clinically available Kv7 channel activator retigabine relaxed rat, guinea pig, 
and human airways in vitro, however an in vivo allergic asthma animal model that 
can be used to examine the therapeutic potential of retigabine to relax airway 





has created a solid foundation for future studies that explore the potential of Kv7 
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